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ABSTRACT 
 
Dynamic Fluorescence Imaging with Molecular Agents for Cancer Detection. 
(December 2006) 
Sun Kuk Kwon, B.S., Hanyang University 
Chair of Advisory Committee: Dr. Eva M. Sevick-Muraca 
 
 Non-invasive dynamic optical imaging of small animals requires the 
development of a novel fluorescence imaging modality.  Herein, fluorescence imaging is 
demonstrated with sub-second camera integration times using agents specifically 
targeted to disease markers, enabling rapid detection of cancerous regions.  The 
continuous-wave fluorescence imaging acquires data with an intensified or an electron-
multiplying charge-coupled device.  The work presented in this dissertation (i) assessed 
dose-dependent uptake using dynamic fluorescence imaging and pharmacokinetic (PK) 
models, (ii) evaluated disease marker availability in two different xenograft tumors, (iii) 
compared the impact of autofluorescence in fluorescence imaging of near-infrared (NIR) 
vs. red light excitable fluorescent contrast agents, (iv) demonstrated dual-wavelength 
fluorescence imaging of angiogenic vessels and lymphatics associated with a xenograft 
tumor model, and (v) examined dynamic multi-wavelength, whole-body fluorescence 
imaging with two different fluorescent contrast agents.   
 PK analysis showed that the uptake of Cy5.5-c(KRGDf) in xenograft tumor 
regions linearly increased with doses of Cy5.5-c(KRGDf) up to 1.5 nmol/mouse.  Above 
  
 
iv
1.5 nmol/mouse, the uptake did not increase with doses, suggesting receptor saturation.  
Target to background ratio (TBR) and PK analysis for two different tumor cell lines 
showed that while Kaposi’s sarcoma (KS1767) exhibited early and rapid uptake of 
Cy5.5-c(KRGDf), human melanoma tumors (M21) had non-significant TBR differences 
and early uptake rates similar to the contralateral normal tissue regions.  The differences 
may be due to different compartment location of the target. 
 A comparison of fluorescence imaging with NIR vs. red light excitable 
fluorescent dyes demonstrates that NIR dyes are associated with less background signal, 
enabling rapid tumor detection.  In contrast, animals injected with red light excitable 
fluorescent dyes showed high autofluorescence. 
 Dual-wavelength fluorescence images were acquired using a targeted 111In-
DTPA-K(IRDye800)-c(KRGDf) to selectively detect tumor angiogenesis and an 
untargeted Cy5.5 to image lymphatics.  After acquiring the experimental data, 
fluorescence image-guided surgery was performed. 
 Dynamic, multi-wavelength fluorescence imaging was accomplished using a 
liquid crystal tunable filter (LCTF).  Excitation light was used for reflectance images 
with a LCTF transmitting a shorter wavelength than the peak in the excitation light 
spectrum.  Therefore, images can be dynamically acquired alternating frame by frame 
between emission and excitation light, which should enable image-guided surgery. 
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NOMENCLATURE 
Abbreviation 
1-D   one dimensional 
3-D   three-dimensional 
a.u.    arbitrary unit 
BBB-D   disruption of the blood-brain barrier 
CCD    charge-coupled device 
CEU   contrast-enhanced ultrasound 
CT   computed tomography 
CW   continuous wave 
CYT-103   B72.3-glycyl-tyrosyl N—dimethylenetriaminepenta-acetic acid 
Cy   cyanine 
EGF    epidermal growth factor 
EGFR    epidermal growth factor receptor 
EPR    enhanced permeability and retention 
ECM    extracellular matrix 
EMCCD  electron multiplication charge-coupled device 
EGFR    epidermal growth factor receptor 
FBP   filtered back projection 
FDG   2-fluoro-2-deoxy-D-glucose 
FDPM   frequency domain photon migration 
FGF   fibroblast growth factor 
Gd    gadolinium 
ICCD    intensifier charge-coupled device 
ICG   indocyanine green 
i.d.   intradermal 
i.v .   intravenous 
LCTF   liquid crystal tunable filter 
MAb   monoclonal antibody 
MAP   maximum a posteriori 
MRI   magnetic resonance imaging 
MVD    microvessel density 
NIR    near-infrared 
OD    optical density 
OSEM   ordered-subset expectation maximization 
PEG   polyethylene glycol 
PET    positron emission tomography 
PK    pharmacokinetic 
PLAP   placental alkaline phosphatase 
R   transmission ratio 
ROI    region of interest 
ROIs    regions of interest 
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RGD    arginine-glycine-aspartic 
S(λm) mean fluorescence intensity values associated with the 
measurements taken in the presence of dye in the solution 
S(λx) mean fluorescence intensity values associated with the 
measurements taken in the absence of dye in the solution 
SNR    signal to noise ratio 
SPECT   single photon emission computed tomography 
SUV    standard uptake values 
SLN    sentinel lymph node 
TK    tyrosine kinase 
TBR    target to background ratio 
 
Symbols 
α   pharmacokinetic parameter 
β   pharmacokinetic parameter 
)(tCBOUND   concentration of dye bound to integrin receptor either in the 
vascular or extravascular compartments 
)(tC LAREXTRAVASCU   concentration of dye in extravascular space 
)(tCVASCULAR    concentration of dye in vascular space 
0I     background fluorescence intensity 
ck  rate constant for distribution of dye from vascular or extravascular 
to bound compartment 
pk  rate constant for distribution of dye from vascular to extravascular 
space 
elk     rate constant for elimination 
rk   reflux rate constant for distribution of dye from extravascular to 
vascular space 
iw     weight function 
t    time 
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1
1. INTRODUCTION 
 Cancer is typically detected and diagnosed through anatomical imaging and then 
subsequent tissue biopsy.  However, tissue biopsy is prone to sampling error and lesions 
of finite volume, thereby providing diagnosis of late rather than early stage disease.  As a 
result, recent research has focused on molecular imaging, which can be defined as the 
imaging of biological processes at cellular and molecular levels in vivo.  Since molecular 
changes precede anatomical changes, molecular imaging may provide diagnostic 
information enabling earlier intervention and greater therapeutic efficacy.  Molecular 
imaging promises to avoid sampling error and provides diagnosis based upon the entire 
diseased site.   
Molecular imaging has been recently garnered attention due to the advances in 
imaging modalities for image acquisition, molecular biology, and novel molecular 
probes.  For successful molecular imaging, the important elements are: (1) highly 
specific molecular probes to  monitor molecular interactions and (2) imaging systems 
with high sensitivity to reporters found at very low concentrations in vivo.  The non-
invasive imaging modalities include magnetic resonance imaging (MRI), X-ray 
computed tomography (CT), positron emission tomography (PET), single photon 
emission computed tomography (SPECT), ultrasound, and optical imaging and have 
varying sensitivities to the reporters.  These imaging modalities depend upon energy-
tissue interaction or the administration of imaging probes as presented in Table 1.1. 
                                                 
  This dissertation follows the style of Journal of Molecular Imaging. 
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 As shown in Table 1.1, MRI and CT imaging system require a substantial 
amount of contrast agents to generate sufficient signal in small animal imaging as well 
as clinical imaging.  In addition, CT provides anatomical imaging, which does not have 
functional information at a molecular level.  Among these modalities, nuclear medicine 
is the “gold-standard” for molecular imaging of cancer.  While nuclear imaging is non-
invasive, provides functional information, and requires small amounts of the contrast 
agents as described in Table 1.1, it has several limitations.  Nuclear imaging requires 
radioactive contrast agents, which are potentially hazardous especially with repeated use.  
Nuclear techniques suffer from limited resolution as well as poor signal to noise (SNR) 
and tumor to background ratio (TBR) when compared with small animal optical imaging 
techniques [7].  In addition, most standard nuclear imaging studies report static images, 
which include information about tracer distribution and receptor densities.  Although 
dynamic nuclear imaging is possible, it requires substantial amounts of contrast agent 
and long integration times. 
Of the previously discussed imaging modalities, optical imaging techniques are 
developing rapidly for use in medicine, because of their sensitivity and use of non-
ionizing radiation.  This technique requires molecularly targeted fluorescent contrast 
agents, since intrinsic contrast in cancerous regions is non-existent or insufficient for 
detection of early metastatic lesions. 
  
 
Table 1.1 Comparison of current molecular imaging modality. 
Imaging modality Depth / resolution What is measured Molecular contrast agents 
X-ray, CT 
 
No apparent limit / 50 
µm 
Attenuation owing to endogenous or 
exogenous compounds Iodinated compound (mM) 
MRI 
 
No apparent limit / 
<100 µm 
Relaxation of spin-spin states of endogenous 
or exogenous paramagnetic compounds 
Lanthanide chelates, Gadolinium, 
dysprosium (mM), ultrasmall iron 
oxide particles (nM) 
Ultrasound 
 mm / 50 µm 
Reflection of sound waves from endogenous 
or exogenous compound that produce acoustic 
mismatches 
Liposomes, microbubbles 
(mM) 
PET 
 
No apparent limit / 
<1~2 mm 
Beta emission from the annihilation of 
exogenous radiotracers 
13N, 11C, 18F, 94mTc, 124I 
(pM ~ nM) 
SPECT 
 
No apparent limit / 
<1~2 mm 
Gamma emission from the annihilation of 
exogenous radiotracers 
99mTc, 111In, 123I, 125I 
(pM ~ nM) 
Optical imaging 
Endogenous (mM) 
Fluorescence (pM-
nM) 
cm / mm 
Attenuation owing to absorbance due to oxy- 
and deoxy- hemoglobin and production of 
fluorescence/luminescence from exogenous 
agents, gene reporters (GFP, RFP), and 
bioluminescence (Luciferin) 
Fluorophores (pM ~ nM) 
Chromophores (mM) 
3 
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Fluorescent contrast agents can be specifically targeted to disease markers within 
cancer, such as those present on the neovasculature, cancer cell surface, or both.  
Therefore, fluorescence imaging techniques may be used as a diagnostic tool for finding 
precancerous or malignant lesions and assessing tumor response.  Imaging tumor 
response to therapy may lead to tailored therapies and increased treatment efficacy.  In 
addition, fluorescence imaging may serve as a surgical tool for resection of lymph nodes 
or tumor margins.   
This thesis reports work toward developing a dynamic, continuous-wave (CW) 
fluorescence-enhanced optical imaging system, which is designed to evaluate the efficacy 
of novel targeted fluorescent contrast agents for in vivo small animal imaging and 
ultimately for clinical imaging.  Fluorescence-enhanced imaging with disease-specific or 
nonspecific contrast agents is in the early stages of clinical translation.  Our current 
studies have emphasized the promising aspects of fluorescence-enhanced imaging 
techniques.  In order to develop dynamic optical imaging for diagnosing cancer and for 
assessing therapeutic efficacy of molecular medicines targeting disease markers, a better 
understanding of the information contained in molecular dynamic optical imaging must 
be obtained from pre-clinical, small animal imaging.  In this work, the integrin receptor 
overexpressed on tumors and on proliferating endothelium is focused upon.  Section 2 
provides a biological background on αvβ3 integrins, especially their role in tumor 
angiogenesis.  In addition, the various molecular imaging modalities which use αvβ3 
targeting are outlined. Section 3 details the instrumentation involved in dynamic 
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fluorescence imaging used to acquire the pharmacokinetic (PK) data reported in the 
subsequent Sections. 
Section 4 is the first Section that describes the experimental work of this thesis 
research.  For molecular diagnostics and therapeutics, it is important to know the optimal 
dose of the agent.  Too much agent could cause receptor oversaturation and expose the 
patient to excess amounts, while too little could cause weak signals and lead to poor 
diagnostic efficacy.  The optimal dose of a diagnostic agent may also provide information 
about the optimal dose of molecular therapeutic agents for individualized therapies. 
Section 4 summaries experimental studies using a three-compartmental PK analysis of 
dynamic in vivo fluorescence data to assess dose-dependent uptake of an integrin targeted 
fluorescent contrast agent following intravenous (i.v.) injection to animals bearing tumors.  
Dynamic imaging has the potential to improve delineation between normal and disease 
tissues and to detect transient alterations in tumor physiology resulting from cancer 
treatment.  In addition, real-time dynamic imaging might help screen drugs and optimize 
treatment procedures.  For example, the action of integrin based therapies differ 
depending upon the location of the integrin receptor, i.e., anti-angiogenesis in the 
vascular space or direct cytotoxicity to cancer cells in the extravascular space. 
Expanded studies of PK models are presented in Section 5, where 
pharmacokinetic models to enable the assessment of disease marker availability in 
potentially different tissue compartments are discussed.  Two three-compartmental PK 
models are used to evaluate the uptake rate of an integrin-targeted fluorescent contrast 
agent in two different xenograft tumor models.    
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 Real-time dynamic whole-body imaging might also be able to monitor circulation 
of the agents through the animal due to its high sensitivity and sub-second camera 
exposure time.  However, the sensitivity of dynamic fluorescence-enhanced imaging can 
deteriorate dramatically owing to inefficient rejection of backscattered excitation light [8] 
and the presence of tissue autofluorescence. Section 6 presents experimental work 
investigating the impact of autofluorescence in dynamic fluorescence imaging of the 
epidermal growth factor receptor (EGFR) with NIR and red light excitable fluorescent 
contrast agents. 
Section 7 presents dual-wavelength fluorescence imaging: specific targeting NIR 
fluorescent conjugates to detect tumor angiogenesis and non-specific red light excitable 
fluorescent dye to detect lymphangiogenesis.  In addition, fluorescence image-guided 
lymphadectomy was described. 
Section 8 presents improved fluorescence whole-body small animal imaging by 
extending dynamic fluorescent imaging to rapid multi-wavelength imaging.  Using a 
liquid crystal tunable filter (LCTF) we monitored multiple fluorescent dyes on different 
conjugates, targeting different tissue compartments all in near rear time with a single 
camera system.   
Figure 1.1 provides the organization of this dissertation.  When combined with 
highly specific molecular probes, sensitive imaging systems, and quantitative analysis 
methods for fluorescence data, dynamic fluorescence-enhanced imaging could provide 
the preclinical validation necessary to translate dynamic, fluorescent optical imaging 
technology into human clinical trials using molecularly targeting agents. 
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Figure 1.1 Organization of dissertation 
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2. BACKGROUND: DIAGNOSTIC IMAGING OF INTEGRIN αvβ3 
2.1 Integrin αvβ3 for Disease Marker for Imaging Angiogenesis 
 Integrins are a large family of transmembrane glycoproteins consisting of two 
subunits, α and β [9].  There are at least 24 distinct integrin heterodimers comprised of 18 
known α subunits and 8 β subunits. Each subunit in an integrin receptor consists of a 
large extracellular domain, a single membrane spanning domain and usually a short 
cytoplasmic domain [10].  Integrins mediate cell to cell and cell to extracellular matrix 
(ECM) adhesion by binding to an arginine-glycine-aspartic (RGD) peptide sequence or a 
non-RGD sequence [11, 12].  Integrin binding to ECM molecules transmits signals from 
inside the cell to the ECM (inside-out signaling) to regulate the affinity and conformation 
of the receptor.  Integrin binding also transmits signals from the ECM into the cell 
(outside-in signaling) to trigger the intracellular events mediated by receptor-ligand 
binding, which can induce changes in gene expression, leading to events such as 
stimulation of cell proliferation or apoptosis [9, 11].  The role of integrins in cancer 
growth is very complex and can differ among cancer types [11].  Integrin expression or 
function can even be different between the primary tumor and its metastases [13, 14].  In 
cancer growth, integrin expression can change during cancer progression from 
overexpression to no expression or the reverse [15]. 
 One of the integrins, αvβ3 is expressed at low levels in most normal tissues 
including intestinal, vascular, and smooth muscle cells, but, is highly expressed in mature, 
bone resorbing osteoclasts, activated macrophages, angiogenic endothelial cells, and 
migrating smooth muscle cells.  These cell types clearly reflect the involvement of 
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integrin αvβ3 in bone resorption, neovascularisation, and inflammation (Figure 2.1).  
Moreover, integrin αvβ3 is also expressed in several invasive tumor types including 
melanoma [16], glioma, ovarian, and breast cancer [17].  Therefore, integrin αvβ3 is an 
ideal target for diagnosing disease as well as for tracking the therapeutic efficacy.  It has 
been shown that antagonists of αvβ3, such as peptides and anti-integrin antibodies, 
induce tumor regression and disrupt newly formed vasculature generated by growth 
factors and tumor fragments, but pre-existing quiescent blood vessels remain unaffected 
[18-20].  
  
Extracellular matrix proteins
Vitronectin, osteopentin, bone sialoprotein, fibronectin, fibrogen, 
von willebrand factor, thrombospondin, proteolysed collagen, and others 
interact
alpha v 
125 kDa
beta 3 105 
kDa
Large 
extracellular 
ectodomain
Cytoplasmic
tails 
Nuclear 
signals 
Nucleus
functions
Cell
Osteoclast mediated 
bone resorptionAngiogenesis
Macrophage 
dependent 
inflammation
Matrix adhesion, 
migration, 
differentiation 
during vessel injury
αvβ3 antagonists 
or antibodies
Tumor 
metastasis
 
Figure 2.1 Schematic of the role of αvβ3 receptors with interaction of ECM molecules.  
Reproduced from [1]. 
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Knockout mice have been used to determine the role of integrin αvβ3.  Although 
knocking out αv or β3 integrin led to developmental abnormalities and defects, neither 
was lethal [21-23].  Additionally, these mice as well as those lacking β5 integrins 
supported developmental angiogenesis [21, 22].  More interestingly, mice lacking β3 
integrins or both β3 and β5 integrins showed enhanced pathological tumor angiogenesis 
[24].   This result is contrary to the previous findings from extensive studies on tumor 
growth using integrin antagonists.  One possible explanation is that when bound to the 
ECM, integrins trigger survival signals. Whereas in the absence of ECM binding, or in 
the presence of endogenous or therapeutic antagonists, the integrins activate a death 
pathway, ‘integrin-mediated death,’ leading to cell death and suppression of angiogenesis. 
Absence of αvβ3 leads to loss of the ability to sense ECM and to trigger endothelial cell 
apoptosis through this pathway, resulting in increased pathological angiogenesis [25]. 
 
2.2  Molecular Imaging Modalities for Imaging αvβ3 
 Although most of the experimental data presented in this dissertation was 
obtained using an optical imaging system to dynamically image integrin αvβ3, it is 
appropriate to discuss briefly the other modalities used for imaging integrin αvβ3. The 
following section contains a description of how the instrumentation works and which 
contrast agents and imaging modalities are used to image integrin αvβ3. 
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2.2.1 Computed Tomography 
 Computed tomography (CT) is a imaging method employing tomography.  A 
schematic of the x-ray CT technique is provided in Figure 2.2.  In MicroCATTM II, which 
is present at the Baylor College of Medicine (BCM) Frensley Center for Imaging 
Research, a rotating frame has an x-ray tube mounted on one side and the detector on the 
opposite side.  The frame spins the x-ray tube and detector around the object, taking a 
large series of 2-D x-ray images around a single axis of rotation.  Each profile is then 
backwards reconstructed by a dedicated computer.  When x-rays pass through the body 
they are absorbed or attenuated at different tissues due to their thickness and densities.  
 
X-Ray tube
X-Ray 
detector
Object
X-Ray beam
Profile
 
Figure 2.2 Schematic of CT imaging technique.  As x-ray tube and detector rotate around 
the object, a series of 2-D x-ray images are taken. 
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 These intrinsic tissue differences, such as bone and fat provide the contrast of 
anatomical structures with high resolution (Figure 2.3 (a) and (b)).  However, CT has 
relatively poor soft-tissue contrast and can generally not differentiate between tumors and 
surrounding soft-tissue.  Although high concentrations of CT contrast agents can be used 
to overcome the sensitivity limitation of CT, they can result in toxicity, limiting repeated 
CT scanning. Nonetheless, the use of contrast agents, such as those for the liver and 
vasculature, is useful to highlight structures that otherwise would be difficult to delineate 
from their surroundings.  Moreover, the visualization software, AMIRA (version 3.1, 
Konrad-Zuse-Zentrum fur Informationstechnik Berlin, Germany) can interactively 
segment different organs or tissue types from the 3D image data after administration of 
contrast agents as shown in Figure 2.3 (c). 
(a) (b) (c)
 
Figure 2.3 CT anatomical (a) whole body image, (b) trabecular bone image, and (c) 
reconstructed image after segmentation from an animal injection with CT liver and 
vasculature contrast agents. 
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2.2.2 Magnetic Resonance Imaging 
 In magnetic resonance imaging (MRI), the nuclei of hydrogen act like small 
spinning bar magnets.  An external magnetic field excites a number of protons in the 
nuclei of hydrogen causing them to align.  The difference between the number of protons 
in the nuclei of hydrogen in the presence and the absence of the magnetic field results in 
a net magnetization in the nucleus of the atoms.  The net magnetization causes the atoms 
to rotate about the axis of the applied electromagnetic field.  When perturbing the 
magnetic alignment using a radio frequency (RF) pulse, the nuclei of the atoms rotate in 
phase and return to their original positions, emitting RF signals, which can be detected by 
gradient coils placed around the object (Figure 2.4).   
 
RF coil
Object
RF input RF output
random aligned
magnetic 
field
Main & gradient 
magnet
 
Figure 2.4 Schematic of MRI technique. Right figure shows that external magnetic field 
aligns protons. When perturbing alignment by a radio frequency (RF) pulse, the nucleus 
of the atoms rotates in phase and returns to their original position, emitting RF signal. 
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 Magnetic resonance (MR) signal depends on the proton density as well as on the 
temporal T1 and T2 relaxation times.  T1 is the time when nuclei placed in the magnetic 
field return to the axis of the original field.  T2 describes the rate of MR signal decay, 
since there are variations in local magnetic field during the signal fade.  Since T1 
relaxation times differ among body tissues, T1 images usually provides anatomical 
details, including differentiation of diseased or abnormal tissue from normal tissue.  T2 
relaxation times also vary in different tissue types.  Most pathological processes increase 
T2 relaxation times, producing a higher signal than the surrounding normal tissue on T2-
weighted scans. 
 Gadolinium (Gd) has been used a successful contrast agent for molecular imaging 
applications.  The Gd chelates are diffusible and serve as markers for detecting tumor 
angiogenesis due to high permeability in tumor region, allowing differentiation between 
normal tissue and malignant tumors.  In addition, its high resolution enables MRI to 
detect tumors that are not visible through x-ray mammography.  Recently, paramagnetic 
nanoparticles have been conjugated with antibodies [26, 27] or peptide/peptidomimectic 
integrin αvβ3 antagonist [28, 29] for imaging of integrin αvβ3 expressed in neovascular 
endothelium.  Sipkins et al. first demonstrated MRI imaging of integrin αvβ3 expressed 
in tumor neovasculature using an antibody against αvβ3, LM 609 conjugated with 
paramagnetic liposomes (300-350 nm in diameter) [26].  Immunohistochemical staining 
confirmed MRI imaging of the integrin on vascular endothelium.  Anderson et al. used 
Gd-perfluorocarbon nanoparticles conjugated to another αvβ3 antibody DM101 (400-700 
nm in diameter) [27].  In their study, neovasculature induced by bFGF was imaged, and 
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the MR signal intensity increased 25 % at 4 hrs after injection of the agent.  An 
atherosclerosis model was also used to image the integrins with a peptidomimetic integrin 
αvβ3 antagonist conjugated to magnetic nanoparticles [28].  In addition, integrin αvβ3 
induced by nascent human melanoma xenografts was detected using targeted 
paramagnetic nanoparticles [29]. Imaging was conducted 12 days after inoculation of 
melanoma cells.  Although MRI has higher spatial resolution as described in Table 1.1, 
MRI is less sensitive.  Therefore, the large amounts of contrast agent, which can be toxic, 
are generally required for obtaining an enhanced contrast.  In addition, contrast agents 
remain in the blood circulation for a long time and may have difficulty penetrating 
tumors due to the large particle size. 
 
2.2.3 Radionuclide-based Imaging 
 Radionuclide based imaging, i.e. nuclear imaging detects emitted gamma rays 
from tissues injected with radioisotopes.  There are two types of nuclear imaging 
techniques; single photon emission computed tomography (SPECT) and positron 
emission tomography (PET). 
 SPECT is a nuclear medicine tomographic imaging technique using gamma rays. 
A schematic of SPECT imaging technique is given in Figure 2.5.  Gamma rays are 
electromagnetic radiation emitted during radioactive decay which has an extremely short 
wavelength.  The radioactive isotope decays and emits gamma rays that can be detected 
by the SPECT detectors. 
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Figure 2.5 Schematic of SPECT imaging technique. Two SPECT detectors rotate around 
an object and detect gamma rays emitted from radionuclides within the object. 
 
 The radionuclides used in SPECT are gamma emitters with relatively long half-
lives (Table 2.1).  In the MicroCAT II, two SPECT detectors rotate around an object 
(usually 360 degrees around an animal), creating a series of 2-D images.  For each image, 
only photons moving perpendicular to the camera face are allowed to pass through the 
collimator.  
 
Table 2.1 Emission energy window and half-life of Radioisotopes frequently used for 
SPECT. 
 
Radioisotope Emission energy (keV) Half-life 
Technetium-99m 140 6 hours 
Iodine-123 159 13 hours 
Iodine-125 27-33 59 days 
Indium-111 171& 245 3 days 
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 The collimator is a pattern of holes through the gamma ray absorbing material 
(tungsten) that projects the gamma ray image onto the detector crystal.  These photons 
originate from various depths in the animal, resulting in overlapping of all tracer emitting 
organs along the specific path. In addition, a multi-head SPECT file which contains data 
from two SPECT files, one from detector # 1 and the other from detector # 2 can be 
merged into a single SPECT data file, resulting in reduced acquisition time and increased 
sensitivity. Furthermore, different isotopes which emit different energies can be 
simultaneously used to image different tissue compartments.  The functional SPECT 
images are collected with anatomical microCT images for enhanced analysis.  Figure 2.6 
shows a fused image of reconstructed SPECT and CT images in an animal injected with a 
bone targeting agent, Technescan. 
 
Figure 2.6 Fused image of reconstructed SPECT and CT images in an animal injected 
with bone targeting agent, Technescan. 
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 PET uses a short-lived radioactive tracer which decays by emitting a positron 
(Table 2.2).  The positrons travel a short distance in the object before striking a nearby 
electron.  When this collision occurs, two gamma rays are simultaneously produced and 
travel away from each other at a 180 degree angle, toward the ring of photon detectors.  
Each time two detectors detect a gamma ray simultaneously, the annihilation event is 
recorded.  A schematic of PET imaging is given in Figure 2.7.   
 With computer controlled vertical and horizontal bed motion, microPET® can 
perform whole body biodistribution or gated imaging with continuous bed motion 
acquisition.  Continuous bed motion acquisitions also afford a higher resolution image for 
static imaging due to over sampling effect caused by the motion. Raw images can be 
reconstructed with several kinds of algorithms, such as 2-D ordered-subset expectation 
maximization (OSEM), 3-D OSEM, 2-D filtered back projection (FBP), 3-D maximum a 
posteriori (MAP).  AMIRA also enables fusion of anatomical CT image and functional 
PET image for enhanced analysis.  Figure 2.8 shows a fused image of reconstructed PET 
and CT images in a human breast cancer (MDA-MB-231) xenograft tumor bearing 
mouse injected with 18F-FDG.  
 
Table 2.2 Half-life of Radioisotopes frequently used for PET. 
Isotope Half-life 
Fluorine-18 110 minutes 
Carbon-11 20 minutes 
Oxegen-15 2 minutes 
Iodine-124 100 hours 
Copper-64 13 hours 
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Figure 2.7 Schematic of PET imaging technique. PET detects two gamma rays 180 
degrees apart after positrons emitted from the object collide with nearby electrons.  
  
 
 
Figure 2.8 Fused image of reconstructed PET and CT images in a human breast cancer 
(MDA-MB-231) xenograft tumor bearing mouse injected with 18F-FDG. 
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 To date, most RGD-based imaging of integrin αvβ3 has been performed using 
nuclear imaging, the “gold-standard” of molecular imaging (Table 2.3).  In SPECT 
imaging, Jenssen et al. [30] used a dimeric RGD peptide E-[c(RGDfK)]2 labeled with 
111In, 99mTc, and 90Y in ovarian carcinoma xenografts.  They demonstrated highly specific 
tumor uptake of 111In-DOTA-E-[c(RGDfK)]2 and 99mTc-HYNIC-E-[c(RGDfK)]2 in 
human tumor xenografts.  In addition, they showed 90Y-DOTA-E-[c(RGDfK)]2 induced a 
significant regression in tumor growth.  111In-RP748, a quinolone∗ that binds to integrin 
αvβ3, was used to image injury-induced vascular proliferation [31].  In addition, Meoli et 
al. [32] used a dual isotope probe with two different energies to image ischemia-induced 
angiogenesis and perfusion.  Furthermore, αP2, a synthesized decapeptide that contains 
two RGD sequences in its structure was labeled with 99mTc to image metastatic tumors in 
human melanoma patients [33, 34].  One patient with αvβ3 positive melanoma showed 
imaging of tumor sites, while imaging of patients with other metastatic tumors was not 
successful.  In these studies, there was no significant toxicity or immune response to the 
high doses.  
PET has been used extensively for αvβ3 imaging, because of its high sensitivity 
and lack of depth limitations (Table 1.1).  A variety of different radiolabeled RGD-
peptides have been developed for non-invasive imaging of integrin αvβ3 expression,  
including peptides labeled with minimum structural alteration, peptide carbohydrate 
conjugates, peptidomimetics based on the RGD-structures, and heterodimeric, 
homodimeric and homotetrameric ligand systems [35].  These peptides were mostly 
                                                 
∗ quinolone: a family of an antibiotic with activity against a wide range of disease-causing bacteria 
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labeled with 18F and 64Cu for imaging in human xenografts or mouse tumor models 
(Table 2.3).  Haubner et al. [16] reported for the first time noninvasive PET imaging of 
integrin αvβ3 expression using [18F]Galacto-RGD in cancer patients.  A patient with 
malignant melanoma stage IIIb and a solitary lymph node metastasis in the right axilla 
showed high uptake of both [18F]FDG and [18F]Galacto-RGD.  Another patient with a 
soft tissue sarcoma dorsal of the right knee joint showed circular peripheral tracer uptake 
in the tumor with variable intensity and a maximum after injection of [18F]Galacto-RGD.  
Although multiple metastases in liver, skin, and lower abdomen in a patient with 
malignant melanoma stage IV were shown with marked uptake of [18F]FDG in the 
lesions, there was no uptake of [18F]Galacto-RGD in the metastatic lesions.  
 
2.2.4 Ultrasound Imaging 
 Ultrasound imaging is based on detecting reflected and transmitted sound waves 
from tissue in response to high frequency sound emitted from a transducer. The 
transducer detects sound waves as they bounce off from internal structures and contours 
(Figure 2.9).  Different tissues reflect these sound waves differently, causing a signature 
which can be measured and transformed into an image.  Ultrasound is commonly used 
due to its low cost, portability, millimeter-range resolution, and non-ionizing radiation.  
Ellegala et al. [36] demonstrated that tumor angiogenesis can be assessed through 
contrast-enhanced ultrasound (CEU) imaging with microbubbles (3-4 µm in diameter) 
targeting integrins.   
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Figure 2.9 Schematic of ultrasound imaging technique. In ultrasound imaging transducer 
detects sound waves bouncing off an object.   
 
 The microbubbles were conjugated to an echistatin peptide bearing a RGD motif.  
The CEU signal was shown to be higher at the periphery of human glioma tumor 
(U87MG), where integrins are prominent as confirmed by immunohistochemistry.  In 
addition, the results from the CEU signal correlated well with the tumor microvessel 
blood volume.  Leong-Poi et al. [37] reported microbubbles conjugated to echistatin or a 
monoclonal antibody (MAb) targeted to αv integrin in mice after 4 days of sustained-
release of fibroblast growth factor (FGF)-2.  Intravital microscopy confirmed the binding 
of microbubbles to endothelium.  The same group also assessed endogenous angiogenic 
responses to ischemia and proangiogenic responses to growth factor therapy [38].  
Recently, when the microbubbles were conjugated with the tumor endothelial-specific 
binding tripeptide arginine-arginine-leucine (RRL) [39],  they selectively bound to 
tumor-derived endothelium.  Ultrasonic molecular imaging of angiogenesis may allow 
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functional assessment of neovasculature as well as monitoring of tumor response to 
antiangiogenic therapies. 
 
2.2.5 Optical-based Imaging 
 Optical imaging is based on launching light onto a tissue surface and detecting the 
scattered and attenuated light. A schematic representation of optical imaging is shown in 
Figure 2.10.  Many endogenous light absorbing molecules are present in biological tissue.  
The absorbance spectra for some of them, oxy- and deoxyhemoglobin, melanin, and 
water, are shown in Figure 2.11.  Although the normal tissues can be differentiated from 
the diseased tissues based upon endogenous contrast in the optical properties such as 
absorption and scattering coefficient, it can be difficult to detect small tumors at early 
stages.   
launching 
light
tissue
detecting 
light
laser detector 
 
Figure 2.10 Schematic of optical imaging. Optical imaging launches incident light on the 
surface of an object and detects the scattered and attenuated light. 
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Figure 2.11 Biological absorbance spectra. Reproduced from Lin and Soter [2]. 
 
 Fluorescent contrast agents have been developed to improve early detection of 
diseased tissues.  Fluorescence refers to the process by which certain molecules absorb 
energy from light at a particular wavelength and re-emit light of a lower energy and 
longer wavelength.  As shown in Figure 2.12, when light of a specific energy (hv1) 
encounters a molecule residing at equilibrium in a ground state S0, the electrons are 
excited to a higher electronic level (S1).  Fluorescence, i.e. photon emission, is generated 
by the relaxation of these electrons back to their ground state, releasing the energy (hv2).  
 We and others (Table 2.3) have shown fluorescence imaging of αvβ3 expressed 
on tumors.  Fluorescence dyes were conjugated to RGD peptides to specifically target 
αvβ3.   
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Figure 2.12 Simplified Jablonski diagram of fluorescence where * represents partial 
dissipation of absorbed energy. Reproduced from Lakowicz and Harris [3]. 
 
 Chen et al. [40] used TBR to show the specificity of Cy5.5-c(RGDyK) in 
subcutaneous U87MG glioblastoma tumor model and reported no correlation between 
changes in TBR and dose.  Subsequently, they showed the effect of the multimers of the 
RGD peptide labeled with Cy5.5 or Cy7 [41, 42].  Their results showed moderate 
improvement in imaging characteristics with the tetramer, as compared to the monomer 
and dimer.  Wang et al. [43] showed dynamic fluorescence imaging of human Kaposi’s 
sarcoma (KS1767) xenografts with Cy5.5- and IRDye800-c(KRGDf).  Recently, the 
dynamic fluorescence intensity as a function of the time was analyzed with a 
pharmacokinetic model [8, 44].  Our work presented in Section 4 showed that the uptake 
of Cy5.5-c(KRGDf) in tumor regions was linearly related to the dose, up to 1.5 
nmol/mouse.  Above doses of 1.5 nmol / mouse, the uptake no longer increased with dose, 
suggesting receptor saturation [8].  In a recent analysis of nuclear and NIR optical 
imaging in which mice bearing human melanoma tumors were injected with a dual-
labeled RGD imaging agent, Houston et al. [7] has shown that fluorescence imaging has 
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significantly higher signal for a given dose of agents, enabling rapid dynamic imaging 
and sensitive detection of diseased regions.  Radionuclide imaging generates a maximum 
of 108 events/sec upon injecting milli-curie amounts of radionuclides.  In contrast, 
fluorescence-enhanced optical imaging can generate almost ~ 1023 events/sec even using 
nanomolar concentrations of the fluorescent agents because they exhibit a fluorescence 
lifetime on the order of nanosecond.  In addition, Houston et al. [45] highlighted the 
sensitivity of contrast-enhanced optical imaging.  They were able to detect a signal of 100 
fmol of the contrast agent located 4 cm below the surface.  Thus, the contrast-enhanced 
optical imaging has the potential to compete with clinically available radionuclide 
imaging techniques.  Because it is an inexpensive, rapid, non-ionizing alternative with 
higher target to background ratio (TBR) to current methods contrast enhanced optical 
imaging should improve upon the currently available imaging modalities.   
 
 
 
 
 
 
 
 
 
 
    
 
Table 2.3 Targeting αvβ3 using the RGD peptide motif with molecular imaging modalities. 
 
Reference Imaging system 
Subject 
Model Tumor model Probe Dose Comments 
Chen et 
al. [46] 
MicroPET 
Autoradio
graph 
Female 
athymic 
nude 
mice(nu/nu)
U87MG 
Glioblastoma 
tumor 
64Cu-DOTA-
PEG-RGD 
For biodistribution: 370 kBq (10 
µCi). For imaging: 14.8 MBq (400 
µCi). For blocking: 10mg/kg 
c(RGDyK) 
Demonstrated the suitability of 
a PEG moiety to improve in 
vivo kinetics of 64Cu-RGD 
Chen et 
al. [47] 
MicroPET
, 
Autoradio
graph 
Female 
athymic 
nude 
mice(nu/nu)
MDA-MB-435 
breast cancer 
64Cu-DOTA-
RGD, 
[18F]FB-RGD,
125I-RGD 
For biodistribution: 10 µCi ( 64Cu-
DOTA-RGD), 
20 µCi ([18F]FB-RGD), 2 µCi (125I-
RGD). For imaging: 200 µCi 
([18F]FB-RGD), 400 µCi ( 64Cu-
DOTA-RGD). For blocking: 
2.5mg/kg c(RGDyK) 
Compared the tumor targeting 
ability and in vivo kinetics and 
showed effective blocking (1hr, 
2.5, 7.5 mg/kg c(RGDyK) ) 
through coinjection with a 
blocking dose c(RGDyK) 
Chen et 
al. [48]  
MicroPET
, 
Autoradio
graph 
Female 
athymic 
nude 
mice(nu/nu)
U87MG 
Glioblastoma 
tumor 
[18F]FB-PEG-
RGD 
For biodistribution: 740kBq (20 
µCi). For imaging: 200 µCi. For 
blocking: 10mg/kg c(RGDyK) 
Demonstrated the suitability of 
a PEG moiety for improving in 
vivo kinetics of [18F]FB-RGD 
Haubner 
et al. [49] PET 
Female 
BALB/c 
mice 
Human M21 
and M21-L 
melanoam 
[18F]Galacto-
RGD 
For biodistribution: 370 kBq. For 
imaging: 5.5 MBq. For blocking: 6 
or 18 mg/kg cyclo(-Arg-Gly-Asp-d-
Phe-Val-) 
Demonstrated 18F-labeled 
RGD-containing glycopeptide 
and noninvasive assessment of 
the blockade of the receptor by 
specific antagonists (10min, 
6,18mg/kg c(RGDfV)) 
Janssen et 
al. [30] Scintigram 
Female nude 
BALB/c 
mice 
Ovarian 
carcinoma 
111In-DOTA-
E-
[c(RGDfK)]2, 
99mTc-
HYNIC-E-
[c(RGDfK)]2, 
90Y-DOTA-E-
[c(RGDfK)]2 
For biodistribution: 370kBq 
(=0.5µg, 111In-DOTA-E-
[c(RGDfK)]2, and scrambled one), 
1.7MBq (=0.04 µg, 99mTc-HYNIC-
E-[c(RGDfK)]2). For receptor 
specificity: 1000-fold excess of 
115In-DOTA-E-[c(RGDfK)]2. For 
imaging: 1.8MBq (111In-DOTA-E-
[c(RGDfK)]2) 
Demonstrated highly specific 
tumor uptake in a human tumor 
xenograft and showed that 
injection of 90Y-DOTA-E-
[c(RGDfK)]2 induced a 
significant regression in tumor 
growth 
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Table 2.3 Continued. 
Reference Imaging system 
Subject 
Model Tumor model Probe Dose Comments 
Haubner 
et al. [50] 
(Also see  
[51]) 
Gamma 
camera 
imaging 
BALB/c 
mice 
Murine 
osteosarcoma 
and human 
M21 
melanoma 
[125I]P2 , 
[125I]GP2, 
[125I]P2, 
[125I]P4, 
[125I]P6, 
[123I]GP2 
For biodistribution: 300 to 400 
MBq ([125I]P2, [125I]P4, [125I]GP2). 
For imaging: 5.6 MBq ([125I]GP2). 
For blocking: 3 or 6 mg/kg cyclo(-
Arg-Gly-Asp-d-Phe-Val-). 
Demonstrated the improvement 
of the pharmacokinetics 
using glycosylation of a 
modified derivative by using a 
sugar amino acid and showed 
the decrease of lipophilicity and 
hepatic uptake 
Winter et 
al. [28] MRI 
Male New 
Zealand 
White 
rabbits 
Atherosclerosis
αvβ3-Integrin-
targeted 
paramagnetic 
nanoparticles 
0.5 Ml/kg body weight, 
0.1mmol/kg gadolinium-DTPA 
Developed a paramagnetic 
nanoparticle contrast agent 
targeted to αvβ3 integrins and 
demonstrated noninvasive 
molecular imaging of  plaque-
associated angiogenesis 
Chen et 
al. [52] 
Optical 
imaging 
Female 
athymic 
nude 
mice(nu/nu)
Glioblastoma 
(U87MG) 
Cy5.5-
c(RGDyK) 
For imaging: 0.1 to 3 nmol. For 
biodistribution: 0.5 nmol 
Demonstrated receptor 
specificity and long-lasting 
tumor accumulation of a RGD-
Cy5.5 conjugate in human 
primary tumor cells in mouse 
xenografts 
Sivolapen
ko et al. 
[33] 
Scintigram 14 patients Metastatic melanoma 
99mTc-αp2 For biodistribution: 100 to 400 µg (185 to 1222 MBq) 
Demonstrated RGD-containing 
synthetic peptide successfully 
ٛocalized metastatic melanoma 
lesions in man, and its in vivo 
profile predisposes of an 
attractive and safe novel 
diagnostic radiopharmaceutical
Hua et al. 
[53] SPECT 
Male 
C57BL/6 
mice 
 
unilateral 
hindlimb 
ischemia 
99mTc-
NC100692 1.5 mCi of 
99mTc-NC100692 
Demonstrated the temporal 
changes in ischemia induced 
angiogenesis as targeting 
integrin αvβ3 
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Table 2.3 Continued. 
Reference Imaging system 
Subject 
Model Tumor model Probe Dose Comments 
Poethko 
et al. [54] PET 
Female nude 
mice 
pancreatic 
tumor 
(AR42J) and 
M21 
melanoma 
 
Gluc-S-
Dpr([18F]FBO
A)TOCA, 
(c(RGDfE)HE
G)2-K-Dpr-
[18F]FBOA 
 
For biodistribution: 1.48 to 2.22 
MBq. For blocking: 0.4 mg Tyr3-
octreotide/kg (10 µg per mouse) or 
18mg c(RGDfV) (360 µg per 
mouse) 
Demonstrated that 
(c(RGDfE)HEG)2-K-Dpr-
[18F]FBOA and Gluc-S-
Dpr([18F]FBOA)TOCA showed 
favorable pharmacokinetics and 
high TBR ratios in vivo 
Chen et 
al. [47] 
MicroPE
T, 
autoradio
graphy 
Female 
athymic 
nude 
mice(nu/nu)
Glioblastoma 
(U87MG) 
[18F]FB-
E[c(RGDyK)]2 
50 µCi (imaging), 20 µCi 
(biodistribution), 10mg/kg 
c(RGDyK) (for blocking 
Experiment) 
Demonstrated that [18F]FB-
E[c(RGDyK)]2 has significantly 
improved tumor targeting 
efficacy compared to [18F]FB-
c(RGDyK) 
Wang et 
al. [43] 
Optical 
Imaging 
Athymic 
nude mice 
KS1767, M21 
or M21-L 
Cy5.5-
c(KRGDf), 
IRDye800-
c(KRGDf) 
For imaging: 3 nmol Cy5.5-
c(KRGDf) and IRDye800-
c(KRGDf). For blocking: 600 nmol 
c(KRGDf) 1 hour before the 
injection of the conjugate at 3 
nmol. 
Demonstrated in vivo near-
fluorescence optical imaging 
and suggested a possible way to 
quantify the impact of dye 
conjugate 
Li et al. 
[55] 
Dual 
optical 
and 
nuclear 
imaging 
Athymic 
nude mice 
M21 and 
M21-L 
111In-DTPA-
Bz-SA-
Lys(Irdye800)-
c(KRGDf) 
For biodistribution: 0.4 
nmol/mouse (12 Ci/mouse). For 　
imaging: 5 nmol/mouse (90 
Ci/mouse). For blocking: 600 　
nmol of c(KRGDf) followed by the 
injection of dual-labeled agent 1 h 
later 
Demonstrated that dual 
modality imaging with dual 
labeled probe can give 
complementary information in 
the assessment of the molecular 
characteristics of various 
disease models. 
Houston 
et al. [7] 
Dual 
optical 
and 
nuclear 
imaging 
Female 
athymic 
nude mice 
M21 and 
M21-L 
111In-DTPA-
Bz-SA-
Lys(Irdye800)-
c(KRGDf) 
For imaging: equivalent dose of 5 
nmol of IRDye800 and 90 µCi of 
111In 
Demonstrated that SNR was 
significantly higher for optical than 
nuclear imaging, and optical 
imaging for the subcutaneous tumor 
targets had greater sensitivity than 
nuclear imaging 
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Table 2.3 Continued. 
Reference Imaging system 
Subject 
Model Tumor model Probe Dose Comments 
Sadeghi 
et al. [31] 
Autoradio
graphy 
Female 
apoE-/- mice
Left common 
carotid artery
111In-quinolone  
(RP748) 7.4 MBq of RP748 for imaging
Demonstrated that RP748 binds to 
activated αvβ3 integrin to track the 
injury-induced arterial 
proliferation in mice 
Meoli et 
al. [32] SPECT 
chronic rat 
and dogs 
injury-induced 
myocardial 
angiogenesis 
111In- RP748, 
99mTc-2-
methoxy-2-
metholpropyl-
isonitrile 
(sestamibi), 
201Tl, 
1.2 mCi of 111In- RP748 and 
0.78 mCi of 201Tl for rat; 6.6 
mCi of 111In- RP748 and 22.3 
mCi of 99mTc- sestamibi for dog
Used dual isotope SPECT imaging 
for imaging ischemia-induced 
angiogenesis and perfusion 
Posey et 
al. [34] 
Gamma 
camera 9 patients 
Metastatic 
cancer 
99mTc-Vitaxin 30 mCi of 99mTc-Vitaxin 
Nuclear imaging of tumor 
vasculature was not successful, 
while one patient with αvβ3 
positive melanoma had imaging of 
tumor sites. In addition, there was 
no immune response to Vitaxin 
(2.5-3.5 mg/kg) 
Van 
Hagen et 
al.  [56] 
Autoradio
graphy 
Male Lewis 
rats 
Rat pancreatic 
tumor 
(CA20948) 
 
125I-DTPA-
RGD 3MBq 
Demonstrated that uptake 
decreased with increasing peptide 
amount and the incorporation of 
the DTPA group in the peptide 
resulted in renal clearance of the 
radiopharmaceutical 
Gurfinkel 
et al. [44] 
 
Optical 
imaging 
Female 
athymic 
nude mice 
Murine 
Kaposi’s 
sarcoma 
(KS1767 ) 
Cy5.5-
c(KRGDf) 
For imaging: 3 nmol. For 
blocking: 600 nmol of 
c(KRGDf) 
Demonstrated the use of a 
pharmacokinetic analysis on in 
vivo fluorescence data to test for 
the specificity of a targeted 
diagnostic fluorescent contrast 
agent in a murine Kaposi’s 
sarcoma model 
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Table 2.3 Continued. 
Reference Imaging system 
Subject 
Model Tumor model Probe Dose Comments 
Haubner 
et al. [16] PET 
Mice and 9 
patients 
M21 and 
M21L, 
chondrosarco
ma, soft tissue
Sarcoma, 
renal cell 
carcinoma, 
villonodular 
synovitis of 
the knee 
[18F]Galacto-
RGD and 
[18F]FDG 
144–200 MBq 
Demonstrated PET imaging of integrin 
αvβ3 expression in cancer patients.  The 
uptake does not correlate with melanoma 
patient tumor grading, since multiple 
metastases in the liver, skin, and lower 
abdomen in a malignant melanoma patient 
were shown with marked uptake of 
[18F]FDG but no uptake of [18F]Galacto-
RGD. 
Chen et 
al. [42] Optical Mice 
Human 
glioblastoma 
(U87MG) 
Cy7-
c(RGDyK), 
Cy7-
E[c(RGDyK)], 
Cy7-
E{ E[c(RGDy
K)]}2 
0.5 nmol 
Showed that there was no advantage of 
dimeric and tetrameric RGD peptides over 
monomeric peptide, while integrin affinity 
of RGD peptide follows the order of 
tetramer>dimmer>monomer.  They 
speculated that the observed higher affinity 
is likely related to receptor clustering 
Chen et 
al. [57] Optical Mice 
Human 
glioblastoma 
(U87MG) 
Cy5.5-
c(RGDyK), 
Cy5.5-
E[c(RGDyK)], 
Cy5.5-
E{ E[c(RGDy
K)]}2 
0.5 nmol 
Showed that multimerization of RGD 
peptide results in moderate improvement of 
imaging characteristics of the tetramer, 
compared to that of the monomer and 
dimeric counterparts. 
Kwon et 
al. [8] Optical Mice 
Kaposi’s 
sarcoma 
(KS1767) 
Cy5.5-
c(KRGDf) 
0.5-6 nmol in 200 ul of 
saline 
Demonstrated the dose dependent uptake of 
Cy5.5-c(KRGDf) to αvβ3 in Kaposi’s 
sarcoma 
Gurfinkel 
et al. [44] 
 
Optical 
imaging 
Female 
athymic 
nude mice 
Murine 
Kaposi’s 
sarcoma 
(KS1767 ) 
Cy5.5-
c(KRGDf) 
For imaging: 3 nmol. 
For blocking: 600 nmol 
of c(KRGDf) 
Demonstrated the use of a pharmacokinetic 
analysis on in vivo fluorescence data to test 
for the specificity of a targeted diagnostic 
fluorescent contrast agent in a murine 
Kaposi’s sarcoma model 
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Table 2.3 Continued. 
Reference Imaging system 
Subject 
Model Tumor model Probe Dose Comments 
Line et al. 
[58] 
Scintigrap
h 
Male SCID 
mice 
DU145 orPC-
3 
99mTc(CO)3-
labeled 
RGE4Cmonom
er, RGE4C 
polymer, 
RGD4C 
monomer, and 
RGD4C 
polymer 
31.2-34.9 nmol (14.8-
18.5 MBq) of 
compounds in 200ul of 
normal saline 
Showed increase in tumor uptake in the 
series RGE4C monomer < RGE4C 
polymer < RGD4C monomer < RGD4C 
polymer, and demonstrated specific 
molecular targeting of the αvβ3 integrin 
and nonspecific vascular permeability are 
both significant in the relative tumor 
localization of polymeric conjugates of 
RGD4C. 
Beer et al. 
[14] PET 19 patients 
Various 
human tumors
[18F]Galacto-
RGD 133-200 MBq 
Correlated the level of integrin αvβ3 
expression with SUV, MVD, and TBR 
using PET in human cancer patients 
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3. INSTRUMENTATION 
 The fluorescence imaging data presented in this dissertation was obtained using 
an intensified charge-coupled device (ICCD) developed in the Photon Migration 
Laboratories or using a commercially available electron multiplication charge-coupled 
device (EMCCD).  This section contains a brief discussion of the ICCD, EMCCD, liquid 
crystal tunable filter, and optical components used for small animal imaging. 
 
3.1 Intensified Charge-coupled Device System 
 The fluorescence-enhanced intensified charge-coupled device (ICCD) system 
instrumentation was developed in the Photon Migration Laboratories.  The main ICCD 
components for continuous wave (CW) imaging are (1) a charge-coupled device (CCD) 
camera, (2) a CCD cooling unit, and (3) a CCD controller, and (4) an image intensifier. 
The CCD camera (model: PI-SCX, Roper Scientific in Tucson, AZ) has 16-bit dynamic 
range with a frame transfer CCD chip.  In addition, it features 1024 x 1024 pixels where 
each pixel is 13 µm in length.  Due to the 16-bit dynamic range, where 2
16 
is equivalent to 
65,536 gray levels, the CCD camera can detect very dim and very bright fluorescent area 
within an image.  In addition, unlike the full-frame CCD that must wait for all charge to 
be readout prior to beginning the next exposure, the frame-transfer CCD has a maximum 
digitation frequency of 5 MHz and has its parallel register divided into two distinct areas; 
the image and storage arrays.  When the CCD is exposed to light, the charge is 
accumulated in the image array.  Then, the accumulated charge in the image array is 
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rapidly transferred to the storage array (in less than 300 microseconds), which enables the 
image array to begin next exposure without the need of a mechanical shutter.   
Quantum efficiency, the fraction of incoming photons that are absorbed by the CCD, 
and system read-out noise, as inherent property of the CCD, are important features which 
affect signal-to-noise ratios at low light levels.  The optimal quantum efficiency of the 
CCD is between approximately 200 to 900 nm. 
 The CCD camera has a fiber bundle that is directly laminated to the square CCD 
chip, enlarging the size of CCD.  Therefore, an image intensifier can be directly attached 
to CCD without loss of resolution.  The image intensifier amplifies low fluorescence 
emission signals, resulting in a better signal to noise ratio (SNR).  The image intensifier 
(Gen. 3 Pinnacle™, model: FS9910, ITT NightVision, Roanoke, VA) was used for the 
small animal imaging presented in Sections 4, 5, and 6. 
 
3.2 Electron-Multiplying Charge-coupled Device 
 Although image intensifier in ICCD camera system amplifies extremely low 
fluorescence signals to enable highly sensitive imaging, the intensifier is susceptible to 
damage when exposed to high signal levels.  In addition, the CCD camera has a 
maximum digitation frequency of 5 MHz, which limits rapid, real-time dynamic 
fluorescence imaging.  Hence, an electron-multiplying CCD (EMCCD) camera (model 
PhotoMAX:512B, Princeton Instruments, Trenton, NJ) was used for dynamic imaging 
without the addition of the image intensifier.  Figure 3.1 shows a schematic of ‘on-chip 
multiplication gain’ which is employed in EMCCD camera system to multiply photon-
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generated charge above the read noise levels at video frame rates.  The multiplication 
gain occurs after the device detects a photon but before the chip read-out amplifier.  In 
the extended multiplication register, the CCD clock voltages, which control gain, 
accelerate electrons from pixel to pixel, resulting in the generation of secondary electrons 
by an impact-ionization process.  Therefore, this process can reduce the CCD read-out 
noise, which is one of the primary noise sources, by varying clock voltage, on-chip 
multiplication gain factor.  The ICCD system employs a 5 MHz, 16-bit digitizer, while 
EMCCD camera uses a 10 MHz, 16-bit digitizer.  Therefore, with ROI selection and/or 
binning, the frame rates in excess of 400 frames per second are possible. 
PhotonMAX is the back-illuminated CCD with dual-amplifiers.  PhotonMAX has 
an active imaging area of 512x512 pixels, where each pixel is 16 µm in length.  In 
addition, it does not require a cooling unit, since deep thermoelectric cooling (-70 C) is 
used to suppress system noise.  The thermoelectric cooling method uses a Peltier cooler 
in combination with air-circulation.  Quantum efficiency is 90 % at 550 nm and 65 % at 
830 nm. This system is used only for CW imaging, since this camera can not modulate 
incoming photons.  PVCAM is a dynamic link library (DLL) of functions.  The imaging 
acquisition software V++ (Digital Optics, New Zealand) uses DLL library of ICCD and 
EMCCD to control the camera and acquire the images.  The EMCCD camera was used 
for the experimental work described in Sections 7 and 8. 
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Sensor area
Frame-transfer area
Normal clock voltage
High clock voltage
Traditional serial register
Extended multiplication register Output
Reamplifier  
Figure 3.1 Schematic of ‘on-chip multiplication gain’ in EMCCD camera system.  
Reproduced from [4]. 
 
3.3  Liquid Crystal Tunable Filter 
 A liquid crystal tunable filter (LCTF) is a birefringent optical filter that can select 
a specific center wavelength for transmission, since the birefringent element is a material 
that displays two different indices of refraction, while rejecting wavelengths outside this 
wavelength band.  LCTF is based on the lyot filter principle.  A lyot filter is made from 
several birefringent plates where each plate is half the thickness of the previous one.  
Since each birefringent plate is surrounded by polarizers, the filter has a spectral 
transmission peak.  While a lyot filter provides a static bandpass, if the filter has 
electrically tunable birefringent elements inserted, an electrically tunable filter can be 
obtained.  As shown schematically in Figure 3.2 (a), each stage consists of an initial 
linear polarizer, a birefringent element, a liquid crystal waveplate, and a final analyzer 
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oriented on an axis parallel to the initial polarizer [5].  The liquid crystal waveplate is 
comprised of two transparent electrodes on either side of a cell filled with nematic liquid 
crystals [5].  The electrodes are normal to the incident light and the alignment of liquid 
crystals is initially perpendicular to the light path (Figure 3.2 (b)).  When a voltage is 
applied across the electrodes, the molecules align with the applied electrical field.  This 
produces a waveplate with an electronically adjustable retardance [5]. 
Linear 
polarizer
Birefringent 
element
Liquid crystal 
waveplate
Linear 
analyzer(a)
(b)
No electric field Electric field
Optical axis
 
Figure 3.2 Schematic of a LCTF single stage (a) and alignment of liquid crystals when a 
voltage is applied across the electrodes (b). Reproduced from Slawson et al. [5] 
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 The LCTF (Varispec: SNIR, Cambridge Research & Instrumentation, Inc., 
Woburn, MA) has a spectral bandwidth of 7 or 10 nm, with a central wavelength 
electronically tunable between 650 and 1100 nm.  Transmittance varies from 18 % at 650 
nm to 67 % at 1100 nm for randomly polarized incident light.  The LCTF has a 20mm 
circular clear aperture.  The response time for altering wavelengths of the filter is 150 ms 
at 25 °C [59]. 
 
3.4  Optical Components and Accessories 
 Fluorescence imaging requires light with an appropriate wavelength source to 
excite a fluorophore.  In the experimental studies in this thesis, we employ laser diodes 
(660-nm, 35-Mw, model HL6501MG, or 785-nm, 80-Mw, model DL7140-201, 
ThorLabs, Inc., Newton, NJ).  For uniform illumination of excitation light on the object 
to be imaged, a plano-convex lens and an optical diffuser are placed in front of the laser 
diode.  In addition, the intensity and wavelength of excitation light are maintained 
constant by a laser diode driver and temperature controller (ThorLabs, Inc., models 
LDC500 and TEC2000, respectively, Newton, NJ).   
 For optimal performance of fluorescence imaging, the optical filters used consist 
of a holographic notch-plus band rejection filter (660 nm center wavelength for Cy5.5 or 
785 nm center wavelength for IRDye800 or indocyanine green (ICG), Kaiser Optical 
Systems, Inc., Ann Arbor, MI) and a bandpass or interference filter (710 nm center 
wavelength for Cy5.5, model F10-710.0-4-2.00 or 830 nm center wavelength for 
IRDye800 or ICG, model F10-830.0-4-2.00, CVI Laser Corporation, Albuquerque, NM) 
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to reject backscattered excitation light and isolate fluorescence light.  A Nikon 50 nm 
f/1.8 zoom AF Nikkor camera lens for ICCD camera system and 28 mm f/2.8 zoom AF 
Nikkor camera lens for EMCCD camera combine the optical filters to provide accurate 
focus adjustment. 
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4. IN VIVO DYNAMIC FLUORESCENCE IMAGING IN XENOGRAFTS 
BEARING HUMAN KAPOSI’S SARCOMA FOR ANALYSIS OF DOSE-
DEPENDENT UPTAKE OF A FLUORESCENTLY LABELED RGD 
TARGETED TO αvβ3 RECEPTORS ∗ 
 Section 4 in this thesis describes the small animal imaging undertaken at the 
University of Texas M. D. Anderson Cancer Center in Houston.  Animal care and 
preparation of fluorescent contrast agents were performed by our collaborators who are 
gratefully and individually recognized in the Acknowledgments section in this thesis.  
Although the data was obtained with our collaborators, the PK analysis of the data was 
performed entirely by the author. The experimental studies in this section are intended to 
analyze the molecular uptake of a molecularly targeting agent in vivo during dynamic 
fluorescence imaging.  The work presented in this section was published in Journal of 
Molecular Imaging and Proceedings of the SPIE. 
 
4.1 Introduction 
 As described in Section 2, the vitronectin receptor, αvβ3, plays an important role 
in tumor metastasis and angiogenesis [60-64], which is the growth of new blood vessels 
from pre-existing vasculatures during tumor growth [61, 65, 66].  This integrin is 
expressed on tumor cells as well as on angiogenic endothelial cells [67-72].  Furthermore, 
it has been shown that antagonists of αvβ3 induce tumor regression and apoptosis of 
                                                 
∗ Reprinted in part with permission from Kwon S, Ke S, Houston JP, Wang W, Wu Q, Li C, and Sevick-
Muraca EM (2005). Imaging Dose-Dependent Pharmacokinetics of an RGD Fluorescent Dye Conjugate 
Targeted to Alpha v Beta 3 Receptors in Kaposi ’s sarcoma. Mol Imaging, 4, 75-87.  Copyright 2005 by the 
Society of Molecular Imaging. 
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angiogenic endothelial cells [72-74], thus implying that the αvβ3 integrin may be as a 
viable therapeutic target.  Therefore, noninvasive imaging methods for quantitative and 
visual monitoring of αvβ3 integrin expression in real-time could provide opportunities for 
assessing therapeutic intervention as well as for detection of metastasis.   
Kaposi’s sarcoma (KS1767), a common cancer in HIV-infected patients [75], is 
characterized by intense angiogenesis producing a highly vascular tumor with concurrent 
elevated αvβ3 expression [76, 77].  Arginine-glycine-aspartic (RGD) has been identified 
as one antagonist of αvβ3 and has been radiolabeled for diagnostic imaging and 
therapeutic purposes.  Table 2.3 contains a list of previous experimental cancer imaging 
studies performed by targeting αvβ3 using the RGD peptide motif.  To date, with the 
exception of a few laboratories [41, 43, 52], all RGD-based imaging has been performed 
using the “gold-standard” of molecular nuclear imaging.  In a recent analysis of nuclear 
and near-infrared (NIR) optical scintigraphy in which xenografts bearing melanoma were 
administered a dual-labeled RGD imaging agent, we have shown that fluorescence 
imaging has significantly higher signal per mass of agent, enabling rapid and dynamic 
imaging [7, 55].  Unfortunately, to date there are no standardized fluorescence imaging 
systems and newly reported evidence from our laboratories suggests that target-to-
background (TBR) values generated from intensity-based fluorescence imaging systems 
which produce planar images may be more likely dependent upon instrumentation rather 
than on the selectivity of the targeting contrast agent [78].    
While tomographic imaging systems are under development in our laboratory as 
well as in others, we have taken advantage of the high signal intensity afforded by 
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fluorescence imaging and have developed dynamic optical imaging system.  This 
modality can determine the rate of fluorescent agent uptake which is not dependent upon 
instrumentation artifacts as TBR may be [8, 78].  In addition, we have shown that 
pharmacokinetic analysis of dynamic optical imaging can provide quantitative 
information relating to the availability of integrin receptor target as caused by the 
administration of unlabeled RGD peptide one hour prior to administration of the targeted 
imaging agent [44].  Our pharmacokinetic analysis assumed three compartments: (i) 
unbound conjugate in the vascular space, (ii) unbound conjugate in the extravascular 
space, and (iii) bound conjugate in the vascular and extravascular spaces as associated 
with proliferating endothelium as well as Kaposi sarcoma cancer cells.  Furthermore, we 
assumed that an unsaturated receptor binding model, which predicts that the rate of 
uptake of fluorescent labeled RGD depends linearly upon its concentration as well as on 
the density of available integrin receptors.  When the administration of agent at large 
doses causes receptor saturation, the rate of uptake should be independent of the 
concentration of administered fluorescently labeled RGD.  However, there is currently no 
means to determine the concentration at which binding is saturated in vivo.  For the 
purposes of molecular diagnostics, it is important to know the optimal dose of agent in 
order to avoid receptor oversaturation and excess administration of the imaging agent.  
The optimal dose of a diagnostic agent may also provide information for the optimal dose 
of molecular therapeutic agents for individualized therapies. However, it is unclear 
whether the administration of a molecular diagnostic or a therapeutic agent is at a level 
which causes saturation of the binding sites in vivo.   
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In this contribution, we demonstrate the use of dynamic optical imaging to assess 
changes in integrin-targeting as a function of agent dose in order to evaluate not only the 
availability of the integrin receptor, but also its expression level.  From a non-invasive 
assessment of the disease marker availability through these dynamic molecular imaging 
approaches, a simplified and sensitive approach for individualized molecular therapies 
can be envisioned.  In the following sections, we present pharmacokinetic models, animal 
and tumor models, and instrumentation used in this study to generate the dose-dependent 
pharmacokinetic response from planar, fluorescence optical imaging.  
 
4.2 Pharmacokinetics 
 The three-compartment pharmacokinetic models which describe molecularly 
specific uptake in the vascular or extravascular compartments are described schematically 
in Figure 4.1.  The models are comprised of the unbound vascular component, unbound 
extravascular component, and the bound component and whether each is associated with 
proliferating endothelium in the vascular space (Figure 4.1 a) or cancer cells in the 
extravascular space (Figure 4.1 b).  In dynamic imaging studies, fluorescence intensity 
was detected at the animal tissue surface, which may be mediated by the time-invariant 
autofluorescence and optical properties of scattering and absorption in the tissue over the 
short period of imaging time, and by the time-dependent concentration of the fluorophore 
within each compartments. 
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(a) 
 
(b) 
Figure 4.1 Description of two three-compartment PK models used to describe the uptake 
of a fluorescent contrast agent by proliferation endothelium in the vascular space (a) and 
cancer cells in the extravascular space.   
 
 The time-dependent fluorescent intensity can be expressed by 
( ) )()()( 321 tCwtCwtCwtI BOUNDLAREXTRAVASCUVASCULAR ++≅ ,              (4.1) 
where ( )tI  is the time-dependent fluorescence intensity and 1w , 2w , and 3w  are 
weighting factors that not only represent the fraction of the vascular, extravascular, and 
bound compartment, respectively, but also account for the attenuation that occurs due to 
light propagation in each compartment.  In the short imaging times employed herein, the 
iw ’s are considered constant.  )(tCVASCULAR  and )(tC LAREXTRAVASCU  represent the 
concentration of unbound Cy5.5-c(KRGDf) in the vasculature and extravascular 
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compartments, respectively while )(tCBOUND  represents the concentration of conjugate 
bound to integrin receptor whether in the vascular (Figure 4.1 (a)) or extravascular 
(Figure 4.1 (b)) compartments. Finally, the time-dependent observed fluorescence 
intensity was solved for both PK models of Figure 4.1 (a) and Figure 4.1 (b) to yield the 
common solution: 
                                    ( ) ( )[ ] ( )[ ]tBtAItI o βα −−+−−+= exp1exp1 ,                              (4.2) 
where 0I  is the background fluorescence intensity level:  
                                                           )0(10 VASCULARCwI = ,                                             (4.3) 
where )0(VASCULARC  is the concentration in vascular compartment at the time of i.v. bolus 
injection of the conjugate.  After subtracting the background intensity, the final time-
dependent observed fluorescence intensity may be expressed as: 
                                    ( ) ( ) ( )1 exp 1 expI t A t B tα β⎡ ⎤ ⎡ ⎤= − − + − −⎣ ⎦ ⎣ ⎦ .                              (4.4) 
 For Figure 4.1 (a) pre-exponential factors are given by: 
                                   ( ) ⎥⎦
⎤⎢⎣
⎡ −−−−−= α
ααβα
3
12
)( wkkwkwkCA rcrpBo ,                         (4.5) 
                                   ( ) ⎥⎦
⎤⎢⎣
⎡ −−−−−= β
βββα
3
21
)( wkkwkwkCB rcprBo ,                         (4.6) 
and for Figure 4.1 (b):  
                                     ( ) ⎥⎦
⎤⎢⎣
⎡ −−−−= ααβα
3
12
wkk
wkwk
C
A pcEESpBo ,                             (4.7) 
                                      ( ) ⎥⎦
⎤⎢⎣
⎡ +−−−= βββα
3
21
wkk
wkwkCB pcpEESBo .                               (4.8) 
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 For Figure 4.1 (a) the time dependent terms are given by: 
                                         ( ) ⎥⎦⎤⎢⎣⎡ +−++= prara kkkkkk 421 22α ,                               (4.9) 
                                         ( ) ⎥⎦⎤⎢⎣⎡ +−−+= prrara kkkkkk 421 2β ,                             (4.10) 
where 
                                                           elpca kkkk ++= ,                                               (4.11) 
and for Figure 4.1 (b): 
                                       ( ) ⎥⎦⎤⎢⎣⎡ +−++= prBEESBEES kkkkkk 421 2α ,                          (4.12)
  
                                       ( ) ⎥⎦⎤⎢⎣⎡ +−−+= prBEESBEES kkkkkk 421 2β ,                          (4.13) 
where  
                                              crEES kkk += , and pelB kkk += .                                   (4.14) 
  
 The kinetic terms are different between the two models and are defined as 
illustrated in Figure 4.1 (a) and (b).  In the initial dynamic imaging of short duration, the 
concentration difference between bound and unbound agent is the greatest and we assume 
reverse binding to be negligible as shown in Figure 4.1.  Furthermore, if dyes do not 
experience specific, molecular targeting, the vascular and extravascular compartments 
may be sufficient to describe their distribution.  However, for dyes with molecular 
specificity, it is necessary to include the third compartment, which represents surface 
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receptor binding and/or cellular uptake at a molecular level.  The rate constant at which 
the dye accumulates in the bound compartment is denoted by ck , regardless of the PK 
model chosen.  
The pre-exponential parameters A and B reflect the magnitude of the detected 
fluorescence signal, which can provide the differentiation between contralateral normal 
and tumor tissue regions within an individual animal.  For both PK models, the 
expression of α + β represents the sum of all rate constants between the various 
compartments: 
                                                    celrp kkkk +++=+ βα ,                                         (4.15) 
which can be exploited as the dose response at various dose amounts in tumor ROIs 
among all animals.  Assuming that all rate constants are unchanged except ck , variation 
of net uptake at different doses in different animals can be attributed to receptor binding.   
Previous work from our laboratory shows that there is no significant difference in the PK 
parameters of α + β of free, non-targeting Cy5.5 dye associated with KS1767 and 
contralateral normal tissues [44]. 
 
4.3 Materials and Methods 
4.3.1 Animal and Tumor Models, and Fluorescently Conjugated RGD 
 Four to six week-old female athymic nude mice (nu/nu; 18 –22 g) were purchased 
from Harlan Sprague Dawley, Inc. (Indianapolis, IN) and housed five per cage and fed 
sterilized pelleted food (Harlan Sprague Dawley Inc., Indianapolis, IN) and sterilized 
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water.  Animals were maintained in a pathogen-free mouse colony in the Department of 
Veterinary Medicine (The University of Texas M. D. Anderson Cancer Center, Houston, 
TX).  The facility is accredited by the American Association for Laboratory Animal Care 
and all experiments were performed in accordance with the guidelines of the Institutional 
Animal Care and Use Committee.  Human Kaposi’s sarcoma (KS1767) cells to be 
implanted into mice were harvested near confluence by incubation with 0.05% trypsin-
EDTA.  KS1767 Cells (2-3 × 106 / animal) were implanted subcutaneously into the hind 
region of mice.   
Cyclo(Lys-Arg-Gly-Asp-Phe)[c(KRGDf)] was synthesized on linker-PL-DMA 
resin using Fmoc solid chemistry at the M.D. Anderson Cancer Center by Dr. Wei Wang 
[43].   
 
4.3.2 Experimental Methods 
 Animals were subdivided into eight test groups (n=3 for each test group) based on 
the dose amount of contrast agent administered.  Six dose groups received different 
amounts of Cy5.5-c(KRGDf), while two blocking groups received RGD peptide at 300 or 
600 nmol one hour prior to the 3 nmol of Cy5.5-c(KRGDf).  Prior to imaging and agent 
administration, mice were anesthetized with Nembutal (Sigma, St. Louis, MO, 50 mg/kg 
bw, i.p.), and a tail vein catheter was introduced in each animal.  Animals were then 
placed on the temperature-controlled water circulation pad (Heat Therapy Pump 
T/Pump®, Model No. TP-500, Gaymar Industries Inc., Orchard Park, NY) at 37 C under 
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isofluorane anesthesia (VetEquip, Pleasanton, CA and IsoSol Isofluorane USP, VEDCO 
Inc., St. Joseph, MO).  Imaging commenced prior to the administration of agent. 
 
4.3.3 Fluorescence Imaging System 
 Figure 4.2 illustrates the experimental apparatus used for small animal 
fluorescence imaging.  A laser diode (35 Mw, 660-nm for Cy5.5 excitation) provided 
excitation light, which uniformly illuminated the whole body of the mouse through a 
convex lens and diffuser.  To reject backscattered and reflected excitation light, a 
holographic notch-plus band rejection filter (660-nm center wavelength; Kaiser Optical 
Systems, Inc., model, Ann Arbor, MI, OD at λx reported to be >6) and a bandpass filter 
(710-nm center wavelength; CVI Laser, model, OD at λx reported to be 3) were 
positioned prior to a 28-50-mm Nikkor lens (Nikon, Japan). Therefore, re-emitted 
fluorescence light and the small amount of leaked excitation light [78] was detected by an 
intensified charge-coupled device (ICCD) camera (Photometrics, model CH350/L, 
Tucson, AZ) coupled to an image intensifier (model FS9910C, ITT Night Vision, 
Roanoke, VA). 
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Figure 4.2 Instrumentation for the intensified charge-coupled device (ICCD) system for 
the small animal imaging. 
 
 When a low-power lamp provided a white-light source for white light images, the 
filters were removed.  All images were acquired by a personal computer with V++ 
imaging software (Digital Optics, Auckland, New Zealand).  Imaging commenced with 
initial white-light images and at least six images serving as “background” images prior to 
bolus administration of the imaging agent.  Dynamic fluorescence images were acquired 
immediately following the injection of contrast agent for approximately 20-mins.  The 
injected dose of Cy5.5-c(KRGDf) was varied from 0.75 to 6-nmol per animal.  The CCD 
integration  time was 3000-msec for the 0.75 nmol dose, 1000-msec for 1 and 1.25 nmol 
doses, and 300-msec for 1.5, 3 and 6 nmol agent doses in order to maintain signal to 
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noise ratio.  Fluorescence images were also obtained under ٛocalizedٛe anesthesia at 24 
and 48 hours after initial injection of the imaging agent at all doses. 
 
4.3.4 Data Processing and Statistics 
 After completion of the image acquisition, data analysis and processing was 
accomplished by Matlab software (The MathWorks, Inc., Natick, MA), SigmaPlot 
software package (SPSS Inc., Chicago, IL), and ImageJ (National Institutes of Health, 
Washington, DC). First, the average of the six background images was subtracted from 
each of the acquired fluorescence images. Using white light images, two regions of 
interest (ROI), (i) the tumor and (ii) the contralateral normal ROI, were defined, each 
having the same numerical surface area.  The mean of the fluorescence intensity within 
each ROI in each fluorescence image was calculated.  Using this data, plots of mean 
fluorescence intensity versus time profiles after agent administration were fitted to 
solution of the pharmacokinetic models.  The statistical analysis was performed with 
SPSS 12.0.1 statistical program (SPSS, Inc., Chicago, Illinois).  The data from the non-
linear least-squares regression were analyzed using one-way ANOVA, LSD, Student t-
test.  The differences were considered significant at p < 0.05. 
 
4.4 Results 
4.4.1 In vivo NIR Fluorescence Imaging 
 Figure 4.3 a presents an example of white light and fluorescence images of a 
xenograft bearing a subcutaneous human Kaposi’s sarcoma on the left anterior limb 24 
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hours after the injection of 3 nmol dose of Cy5.5-c(KRGDf) conjugate.  During all 
acquisition times for all animals, the tumor was detected from the fluorescence images, 
up to 48 hours after agent administration.  Cy5.5-c(KRGDf) was also excreted to the 
bladder as evident from the fluorescent images.  In order to demonstrate the binding 
specificity of the Cy5.5-c(KRGDf), fluorescence imaging  was performed 24 hours after 
injection of 3nmol dose of Cy5.5-c(KRGDf) conjugate but 25 hours after the injection of 
600nmol of c(KRGDf) peptide as a competitive agent.  The examples of white light and 
fluorescent images of the blocked receptor xenografts are illustrated in Figure 4.3.  The 
fluorescence images with the same exposure time are illustrated on the same linear color 
scale to allow for a qualitative comparison.  For all animals (n=3), the fluorescence 
intensity originating from the tumor ROIs was larger when Cy5.5-c(KRGDf) conjugate 
was administered alone as compared to when c(KRGDf) was administered 1 hour prior to 
imaging agent administration. The reduced uptake of Cy5.5-c(KRGDf) resulting from 
preadministration of c(KRGDf) validates the in vivo molecular specificity of the 
conjugate to αvβ3 receptors [44]. 
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Figure 4.3 White-light images (left column) and Fluorescence images (right column) 24 
hours after the administration of (a) 3 nmol of Cy5.5-c(KRGDf) conjugate alone, (b) 
RGD-Cy5.5 conjugate 1-hour after the injection of 600nmol of RGD peptide. The white 
arrows on the fluorescence images indicate the location of the xenografted Kaposi’s 
sarcoma tumor. 
 
4.4.2 Dynamic Fluorescence Imaging 
 Figure 4.4 displays the fluorescence intensity (in arbitrary units) in (a) selected 
tumor and (b) corresponding normal tissue ROIs as a function of time after 
administration for one of three animals injected with 0.75, 1.5, and 3 nmol doses of 
Cy5.5-c(KRGDf) and one of three animals injected with 3 nmol dose of conjugate one 
hour after administration of 600 nmol of c(KRGDf).  It also shows the results of the 
Normal Tumor
Normal Tumor
(a)
(b)
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regression and the corresponding least-squares fit. The coefficient of determination R2 for 
the regression was 0.99 or greater in all cases.  As shown in the Figure 4.4, the 
fluorescence intensities in tumor ROIs are higher than those in their corresponding 
normal ROIs.  The figure also shows fluorescence intensities with the conjugate 
administered at 0.75 nmol are the highest, because of the longer camera integration time 
of 3000 msec in comparison to the 300 msec integration times employed for the other 
dosages.  When compared to intensities from 1.5 nmol dose of the conjugate alone, 
fluorescence intensities resulting from 3 nmol dose of the conjugate 1 hour after injection 
600 nmol of c(KRGDf) are higher with the same integration time. 
A ratio of the target (tumor ROI) to background (contralateral normal tissue ROI) 
fluorescence intensity normalizes against differing CCD integration time, since both 
tumor and normal tissue are collected in the same animal using the same image 
acquisition parameters. However, TBR may fail to account for differences in the 
fractional contribution of excitation light leakage [78], non-uniformity of excitation 
illumination, as well as the background autofluorescence which results from the red 
excitation wavelength.  Figure 3.5 shows the average and standard deviation of the TBR 
for four groups of animals in the injection of Cy5.5-c(KRGDf) at doses of 0.75 (n=3), 1.5 
(n=3), 3 nmol (n=3) and 3 nmol 1 hour after injecting 600 nmol of c(KRGDf) (n=3) as a 
function of time after administration. 
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Figure 4.4 Fluorescence intensity vs. time profiles from the animal that received an 
injection of the Cy5.5-c(KRGDf) conjugate at 0.75 nmol ( ), 3 nmol ( ), 3 nmol 1 
hour after the injection of 600nmol of c(KRGDf) ( ), and 1.5 nmol ( ) from above, 
acquired from the (a) tumor and (b) normal ROIs. 
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 Figure 4.5 shows that the mice administered 0.75 nmol of the conjugate have the 
highest TBR while the mice administered 1.5 nmole have the lowest TBR. Furthermore, 
the TBR of mice injected with 600 nmol of c(KRGDf) prior to the injection of 3 nmol of 
Cy5.5-c(KRGDf) is higher than one of mice injected with 1.5 nmol of the conjugate. 
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Figure 4.5 The ratio of the tumor to normal ROIs’ intensities. The closed circles (●), 
triangles (▲), and squares (■) denote data from an animal receiving 0.75 nmol, 3 nmol, 
and 1.5 nmol of Cy5.5-c(KRGDf), respectively. The open circles (○) denote the mouse 
injected with 3nmol of Cy5.5-c(KRGDf) conjugate after the injection of 600nmol of 
c(KRGDf). The points represent the mean value of the test group and the error bars the 
standard deviation. 
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4.4.3 Pharmacokinetic Analysis 
 Figure 4.6 shows that the PK values of A and B in tumor region are higher than 
those in normal tissue region in each animal.  The values of A and B are not only 
dependent upon the concentration of injected fluorophore but also vary with experimental 
conditions such as detector sensitivity, incident excitation fluence, and light leakage 
through optical filters.  Therefore, A and B are not solely representative of the molecular 
specificity of conjugate uptake among all test groups in tumor ROIs but instead may 
reflect filter light leakage, integration time, autofluorescence, camera and intensifier gain, 
etc.  However, because the exponential factors α and β are dictated only by the shape of 
the fluorescence intensity vs. time profiles rather than the magnitude of detected signal, 
they may be directly comparable between different experimental trials utilizing the same 
contrast agents regardless of the exposure time, differences in incident excitation fluence, 
as well as excitation light leakage through optical filters.  Figure 4.7 shows that for all 
test groups the sum of α and β in normal ROIs from images resulting from different 
dosages of conjugate are not statistically different (p = 0.86), while those in tumor ROIs 
are different (p < 0.0001) and apparently depend upon the administered dose of imaging 
agent.  The PK value of α + β in the tumor region with the conjugate alone is the lowest 
at the dose of 0.75 nmol, and the highest at 1.5 nmol.  The figure shows a linear 
relationship between the dose amount and α + β for tumor ROIs for doses up to 1.5 nmol 
of Cy5.5-c(KRGDf).  The PK value of α + β in tumor ROIs of mice injected with a dose 
of 0.75 nmol is significantly different (p < 0.02) compared to the corresponding values 
for mice injected with doses ranging from 1.25 to 6 nmol.   
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Figure 4.6 Results of the pharmacokinetic pre-exponential factors (a) A and (b) B after 
the non-linear least-squares regression. The column height represents the mean value of 
the test group (n=3 for each group) and the error bars represent the standard deviation. 
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 Also, the value of α + β in tumor ROIs of mice injected at 1 nmol dose is 
statistically different (p < 0.05) from those values arising from doses ranging from 1.5 to 
6 nmol.  However, there is no significant difference in the values of α + β associated with 
tumor ROIs when Cy5.5-c(KRGDf) dose is varied from 1.5 to 6 nmol (p = 0.25).  The 
PK parameters of α + β in the normal and tumor ROIs are not statistically different when 
free c(KRGDf) is pre-administered at doses of 300 or 600nmol 1 hour prior to 
administration of Cy5.5-c(RGDf) [44]. There is also no difference of α + β values in 
either normal or tumor ROIs between of blocking groups receiving c(KRGDf) prior to 3 
nmol of the conjugate and the dose group of animals receiving 0.75 nmol of the conjugate 
alone. 
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Figure 4.7 The sum of the pharmacokinetic constants α and β in the tumor and normal 
ROIs.  The column height represents the mean value of the test group and the error bars 
represent the standard deviation. 
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4.5 Discussion 
 In this study, we demonstrated the advantages of dynamic imaging for dose-
dependent uptake and compared the resulting pharmacokinetic values with the 
conventional measurement of TBR.  As shown in Figure 4.4, the acquired fluorescent 
intensities within selected ROIs are dependent not only on agent dose, but also on the 
camera integration times, which are varied in order to collect comparable signal to noise 
at the varying doses.  For example, the fluorescence intensities in tumor and tissue ROIs 
at 0.75 nmol Cy5.5-c(KRGDf) dose integrated over 3000 msec are larger in comparison 
to those from 3 nmol dose integrated over 300-msec (Figure 4.4). While the ratio of 
fluorescent counts of tumor to normal tissue ROIs, or the TBR, may normalize out the 
variation of integration times, systematic biases owing to excitation light leakage [78], 
autofluorescence, and variation in excitation light illumination with animal position or 
viewing angle [52] nonetheless alters TBR.  Contribution of systematic biases to TBR 
becomes more pronounced with increased integration time.  For example, Figure 4.5 
shows the highest TBR for the lowest dose (0.75 nmol) but the highest integration time 
(3000 msec).  Chen et al. [52] also used TBR to show the specificity of Cy5.5-conjugated 
RGD peptide in subcutaneous U87MG glioblastoma tumor model as a function of dose, 
but also noted changes in TBR that were unrelated to dose. Using a non-intensified CCD, 
their integration times were 120 sec for doses of 0.1, 1.5, and 3 nmol as opposed to our 
integration times of 300-msec at the dose of 1.5, 3, and 6 nmol and 1-3 seconds at 0.75, 1 
and 1.25 nmol.  A detector with increased sensitivity enables image acquisition over 
shorter integration times with reduced contribution of systematic bias in TBR.  For the 
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red excitable dye such as Cy5.5, the endogenous autofluorescence and the fluorescence 
owing to chow may contribute to a higher systematic noise level that when utilizing a 
near-infrared fluorophore.  In addition, the use of combined holographic and interference 
filters sets along with a narrow band illumination source, as used herein, reduces the out-
of-band signal and the systematic noise level.  Owing to the artifacts which impact it, 
TBR may not be a valid optical imaging metric for elucidating the dose dependent uptake 
in normal versus diseased tissues.    
While we were unable to obtain a consistent dose response from fluorescent 
intensity and TBR for the reasons written above and elsewhere [8, 78],  Figure 4.7 shows 
that the PK parameter estimate, α + β  (which contained only the compartment rate 　
parameters as shown in equation (3.15)) produced a consistent dose response.   Figure 4.7 
shows that α + β in the tumor ROI varied linearly with dose from 0.75 nmol to 1.5 nmol, 
with statistical difference between these amounts indicating unsaturated receptor binding 
mechanisms.  Figure 4.7 also shows that the value α + β at the dose of 0.75 nmol of 
Cy5.5-c(KRGDf) alone is similar to  that at 3 nmol dose 1 hour after the injection of 300 
or 600 nmol of c(KRGDf).  The ultra low dose may result in accumulation and selective 
compartmentalization to the kidney, spleen, and bladder rather than to tumor region [16].  
However, the values of α + β remained statistically similar for the 1.5 nmol to 6 nmol 
doses (p = 0.25) in the tumor ROI and for all doses in the normal tissue ROIs (p = 0.86), 
which is indicative of a dose independent response.  This dose independent response is 
consistent with literature reports and may be due to saturated or unavailable receptors for 
molecular targeting or due to partial self-inhibition at high doses.  Chen et al. [52] 
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suggested partial self-inhibition of αvβ3 integrin specific uptake in U87MG at a 3 nmol 
dose of Cy5.5-c(KRGDf) similar to what they reported for targeting gastrin-releasing 
peptide receptor using MicroPET techniques [48].  Hagen et al. [56] investigated the 
tissue distribution of the targeted radiotracer, 111In-DTPA-RGD at doses of  0.1 or 0.5 µg 
administered with and without 100 µg of the unlabeled RGD peptide as a competitive 
ligand.  They showed that the uptake in CA20948 pancreatic tumor was the highest for 
0.1 µg 111In-DTPA-RGD.  Zitzmann et al. [74] showed that RGD-4C-FITC peptide can 
bind to both endothelial cells and tumor cells in human breast cancer xenografts in nude 
mouse.  Using in vitro confocal microscopy, Castel et al. [79] showed that RGD peptide 
targeted to αvβ3 was internalized by integrin-independent, fluid-phase endocytosis 
pathways in both integrin expressing and non-expressing melanoma cells.  They showed 
that the number of functional integrin receptors at the cell surface remains constant after 
one hour following incubation with RGD peptide, while it decreased after incubation 
with monoclonal antibody (mAb 17E6). Furthermore, they demonstrated that high 
concentrations of RGD peptide may be required to induce apoptosis.  Kok et al. [80] 
showed that the in vitro specific binding of radiolabeled RGD-protein conjugates to the 
αvβ3 integrin in H5V endothelial cells seemed to exhibit saturation, but the binding 
plateau was not reached even at the highest concentrations.  However, while these in vitro 
cell culture studies may reflect the binding of integrins on the cancer cells or proliferating 
endothelium, they do not reflect the combined binding in both vascular and extravascular 
compartments which occurs in vivo.   
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To relate our in vivo dynamic imaging to integrin binding, we developed two 
distinct models for binding in the vascular compartment associated with proliferating 
endothelium (Figure 4.1 (a)) as well as the extracellular compartment associated with 
cancer cells (Figure 4.1 (b)).  Conveniently, the solutions for the time-dependent 
fluorescent intensity from both models are similar and the expressions for α + β are 
exactly the same.  Even though it is difficult to relate each PK rate constant to 
physiologically relevant values, the grouped value of α + β allows us to compare the dose 
dependence among all animals.  In contrast to the grouped PK value of α + β the pre-
exponential factors A and B indicate the magnitude of fluorescence intensities.  Each 
value is higher in tumor region than in normal region in each individual animal (Figure 
4.6).  
The ability to estimate receptor densities from in vivo kinetic uptake analysis of 
radiopharmaceuticals has been reported. For example, Vera et al. [81] measured the 
receptor concentration, as well as forward and reverse binding rate constants of 99m-
galactosyl-neoglycoalbumin with biodistribution data.  With dynamic optical imaging, it 
may be possible to likewise measure the receptor density.  Previously, Gurfinkel et al. 
[44] used the PK model of Figure 4.1 (a) to analyze uptake of free Cy5.5, Cy5.5-
c(KRGDf) conjugate administered alone as well as with free c(KRGDf) administered as a 
competitive ligand 1-hour and 24 hours after the injection of Cy5.5-c(KRGDf).  They 
inferred the uptake rate constant owing to integrin binding from differences in Cy5.5-
c(KRGDf) uptake with and without c(KRGDf).  Those studies did not evaluate the dose 
response of uptake due to in vivo binding.  Using a dual-labeled optical and nuclear tracer, 
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we [55] have embarked on the evaluation of in vivo biodistribution data which should 
provide information for quantifying receptor density.  Optical tomography for 
quantitative 3-D imaging of NIR agents in small animals may overcome not only a 
requirement for dual labeled probe by providing biodistribution data directly, but also 
enable molecular imaging of orthotropic tumors.  While phantom studies have 
demonstrated  the possibility of optical tomography into deep tissues [82], to date small 
animal tomography remains under development in several laboratories including our own 
[83] and must be properly validated before being employed for kinetic analysis for 
determination of receptor densities.   
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5. CAN DYNAMIC IN VIVO FLUORESCENCE IMAGING ASSESS TISSUE 
COMPARTMENT OF MOLECULAR TARGET LOCATION? 
 Although PK analysis in Section 4 shows the uptake rate of Cy5.5-c(KRGDf) to 
αvβ3  was linearly related to administered dose [8], consistent with a model of 
unsaturated receptor binding, it did not differentiate between the different compartments 
of integrin binding, i.e. αvβ3 receptors expressed on tumor cells within the extravascular 
space and on proliferating endothelial cells within the vascular space.  Building upon the 
results of the previous section, the experimental studies described in this section are 
intended to examine a second tumor model with known αvβ3 expression on the cancer 
cells, namely the xenograft of human melanoma (M21), to see if dynamic fluorescence 
imaging can differentiate between the vascular and extravascular expression of αvβ3 
integrin.  Kaposi’s sarcoma, a frequent cancer in HIV-infected patients, is richly 
vascularized, characterized by intense angiogenesis, and has high αvβ3 expression in the 
vascular space [75, 84-86].  However, the cell line M21 is known to highly express αvβ3 
on the cancer cells themselves and the tumorigenicity of melanoma is correlated to αvβ3 
expression [87-89].  Therefore, PK analysis with dynamic fluorescence imaging is used 
to differentiate whether the binding of Cy5.5-c(KRGDf) to αvβ3 integrin occurred on 
either the proliferating endothelium within the vascular space or on the tumor cells within 
the extravascular space, which may guide the action of therapeutic intervention 
depending upon the location of the integrin receptor, i.e., anti-angiogenesis in the 
vascular space or direct cytotoxicity to cancer cells in the extravascular space 
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5.1 Materials and Methods 
5.1.1 Imaging Agents, Tumor Cell Lines, and Animal Models 
 The synthesis of the fluorescent imaging agents was conducted by Dr. Wei Wang 
[43].  M21 and KS1767 cells (2-3 × 106 / animal) were implanted subcutaneously into the 
hind region of mice.  Four to six week-old female athymic nude mice (nu/nu; 18 –22 g) 
were purchased from Harlan Sprague Dawley, Inc. (Indianapolis, IN) and housed five per 
cage and fed sterilized pelleted food (Harlan Sprague Dawley Inc., Indianapolis, IN) and 
sterilized water.  Animals were maintained in a pathogen-free mouse colony in the 
Department of Veterinary Medicine (The University of Texas M. D. Anderson Cancer 
Center, Houston, TX) and in the Frensley Center for Imaging Research in the Critical 
Care Medicine (CCM) (Baylor College of Medicine, Houston, TX).  The facilities are 
accredited by the American Association for Laboratory Animal Care and all experiments 
were performed in accordance with the guidelines of the respective Institutional Animal 
Care and Use Committee.   
 
5.1.2 In vivo Dynamic Fluorescence Imaging and Experimental Methods 
 The dynamic fluorescence optical imaging system used in this section is the same 
as represented in Section 3.  Mice were imaged when the tumor size reached 
approximately 6 to 10 mm in diameter.  Prior to imaging and agent administration, mice 
were anesthetized with Nembutal (Sigma, St. Louis, MO, 50 mg/(kg bw) i.p.), and a tail 
vein catheter was introduced in each animal.  Animals were then placed on the 
temperature-controlled water circulation pad (Heat Therapy Pump T/Pump®, Model No. 
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TP-500, Gaymar Industries Inc., Orchard Park, NY) at 37 C under isofluorane anesthesia 
(VetEquip, Pleasanton, CA and IsoSol Isofluorane USP, VEDCO Inc., St. Joseph, MO).  
Fluorescence images were acquired for approximately 20 min immediately following i.v. 
administration of 6 nmol and 3 nmol doses of Cy5.5-c(KRGDf).  For competitive binding 
studies, a 600 nmol dose of unlabeled c(KRGDf) was administered one hour prior to the 
Cy5.5-c(KRGDf).  The animals bearing KS 1767 xenografts received 3 nmol and M21 
xenografts bearing animals received 6 nmol of the Cy5.5-c(KRGDf).  The CCD 
integration time was 300-msec for KS1767 and 800-msec for M21 tumor bearing animals.  
 
5.1.3 Data Analysis, Processing and Statistical Methods 
 The PK models used to analyze dynamic fluorescence images were the same as 
described in Section 3.  Data analysis was accomplished by Matlab software (The 
MathWorks, Inc., Natick, MA), SigmaPlot software package (SPSS Inc., Chicago, IL), 
and ImageJ (National Institutes of Health, Washington, DC) after completion of the 
image acquisition.  First, the average of the background images was subtracted from each 
of the acquired fluorescence images.  Tumor and normal region of interests (ROIs) were 
defined from white light images.  The mean of the fluorescence intensity within each ROI 
in each fluorescence image was then calculated.  TBR was calculated by dividing the 
mean intensity in the tumor ROI by that in the contralateral normal ROI.  The mean time-
dependent fluorescence intensity profiles were fit by non-linear regression of grouped 
value in Equation (3.15), and the sum of the parameter estimates α + β  and TBR were 
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compared with student t-test SPSS 12.0.1 statistical program (SPSS, Inc., Chicago, 
Illinois).  p < 0.05 is considered as significant difference.  
 
5.2 Results 
5.2.1 Western Blot 
 It is important to record cell culture passage number, since tumor cells show 
different characteristics depending upon passage numbers or types of confluent tissue 
culture dishes.  Although we did not record this information, the western blot analysis at 
protein level was performed before inoculation of KS1767 and M21 cells into mice to 
know whether both cells express integrin αvβ3.  Figure 5.1 shows that the amount of 
αvβ3 from both cell lines was almost equal.  Therefore, we confirmed that both cancer 
cell lines expressed αvβ3 integrin equally. 
 
Integrin α v
β-actin
M21               KS1767          M21-L
 
Figure 5.1 Western blot of M21, M21-L, and KS1767 provided by Dr. Shi Ke.  
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5.2.2 Fluorescence Intensity vs. Time Profiles 
 Figure 5.2 shows the fluorescence intensity vs. time profiles for tumor and the 
corresponding contralateral normal tissue ROIs for an example set of animals bearing 
Kaposi’s Sarcoma (Figures 4.2(a) and (b)) and melanoma M21 (Figures 4.2(c) and (d)).  
The symbols denote the mean fluorescence intensity within the integrated regions after 
the injection of Cy5.5-c(KRGDf) at doses of 6 nmol (black), 3 nmol (red), and 3 nmol 1 
hour after the injection of 600nmol of c(KRGDf) (KS1767; green), or 6 nmol 1 hour after 
the injection of 600nmol of c(KRGDf) (M21; green).  The fluorescence intensity was 
maximum for the 6 nmol dose of Cy5.5-c(KRGDf) and the lowest for 3 nmol (KS1767) 
or 6 nmol (M21) dose of Cy5.5-c(KRGDf) 1 hour after the injection of 600 nmol dose of 
c(KRGDf) in both tumor models.  In addition, the fluorescence intensities from tumor 
ROIs were higher than those from contralateral normal ROIs in all groups.  Figure 5.2 
also shows a small transient peak in intensity at 7 seconds in the M21 tumor ROI in after 
the injection of 3 and 6 nmol doses of Cy5.5-c(KRGDf).  This small transient peak is 
neither shown in normal ROIs nor in KS1716 ROIs.  Finally, Figure 5.2 shows the results 
of the least-square fit of the PK model to the fluorescence intensity vs. time profiles in 
each group. The coefficient of determination R2 for the regression was 0.99 for KS1767 
and 0.95 for M21. 
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Figure 5.2. Fluorescence intensity vs. time profiles from tumor and normal ROIs in 
animals bearing KS1767 ((a) and (b))and M21 ((c) and (d)).  Animals received an 
injection of the Cy5.5-c(KRGDf) conjugate at doses of 6 nmol (black), 3 nmol (red), and 
3 nmol 1 hour after the injection of 600nmol of c(KRGDf) (KS1767; green), or 6 nmol 1 
hour after the injection of 600nmol of c(KRGDf) (M21; green). 
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5.2.3 Target to Background Ratio 
 Figure 5.3 shows the histograms of TBR values from xenografts bearing KS1767 
and M21 at times of 10 min (black bars) and 24 hours (white bars) after the injection of 3 
and 6 nmol of Cy5.5-c(KRGDf) and after injection of unlabeled c(KRGDf) followed one 
hour later by Cy5.5-c(KRGDf).  For KS1767, the values of TBR at 10 min and 24 hours 
were statistically different from those values measured when c(KRGDf) was 
administered as a competitive ligand (p<0.05).  Furthermore, the TBR values in the 
KS1767 model decreased with time after the injection of 3 and 6 nmol of Cy5.5-
c(KRGDf) (p<0.05).  Perhaps indicative of the enhanced permeability associated with 
anti-angiogenesis action of RGD, the TBR values computed from images acquired 10 
min after the injection of 3 nmol dose of Cy5.5-c(KRGDf) with pre-administration of 600 
nmol dose of c(KRGDf) were higher than the TBR values computed from images 10 
minutes after 300 nmol dose of c(KRGDf) (p<0.05).  In contrast to the KS1767 model, 
Figure 5.3 shows there were no significant differences between the TBR values in the 
M21 model even when unlabeled c(KRGDf) was administered one hour before Cy5.5-
c(KRGDf) as a competitive ligand. 
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Figure 5.3 Tumor to background ratio (TBR). The filled and unfilled columns denote 
mean value of each test group 10 min and 24 hour after the injection of the Cy5.5-
c(KRGDf), respectively, and the error bars represent the standard deviation.  
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5.2.4 Pharmacokinetic Analysis 
 Figure 5.4 illustrates the sum of the parameter estimates of α + β obtained from 
regression of fluorescence intensity vs. time profiles within tumor (black bars) and 
normal (white bars) ROIs.  The values of α + β in tumor ROIs from xenografts bearing 
KS1767 injected with 3 and 6 nmol doses of Cy5.5-c(KRGDf) are statistically different 
from those in corresponding normal ROIs in KS1767 (p<0.001) except when 600 nmol of 
c(KRGDf) was pre-administered as a competitive ligand.  In contrast, PK values of α + β 
in tumor ROIs and contralateral normal ROIs from xenografts bearing M21 are not 
significantly different among all test groups.  Finally, there is no significant difference of 
PK values of α + β in the normal tissue ROIs across all doses regardless of whether pre-
administration of unlabelled c(KRGDf) occurred.        
 
5.3 Discussion 
 Since the interstitial diffusion coefficient and microvascular permeability of small 
molecules (MW<2000) is almost equal in normal and neoplastic tissue [43], the uptake of 
peptide tracers in tumor region would not be expected to benefit from enhanced 
permeability and retention (EPR) effect.  Additionally, peptides targeting markers 
expressed in the vascular space do not need to diffuse into the extravascular space [58].   
 In this study, we demonstrated dynamic fluorescence imaging and early-time PK 
data for 20 mins after agent delivery to compare the differences in tumor biology of 
human Kaposi’s sarcoma (KS1767), a cancer of the vasculature characterized by intense 
angiogenesis, and a human melanoma tumor line (M21) known to express integrin αvβ3. 
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Figure 5.4 The sum of the PK constant α and β in the tumor (black columns) and normal 
(gray columns) ROIs.  The column height represents the mean value of the test group and 
the error bars represent the standard deviation. 
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 KS1767 and M21 cell lines express comparable levels of the integrin αvβ3 
receptor as shown in Figure 5.1, but when grown as a the xenograft model or found 
within patients, the integrin expression may occur in potentially different tissue 
compartments: (i) on the proliferating endothelium within the vascular space, and/or (ii) 
on the surface of cancer cells in the extravascular space.  While Kaposi sarcoma is a 
vascular cancer and integrin expression should be predominantly located in the vascular 
space, the M21 melanoma xenograft model may require host - cell signaling to induce 
angiogenesis.  Consequently, while M21 cells express αvβ3, the vascular integrin 
expression in the xenografted M21 model may approach that of normal epithelium.  As 
shown by Beer et al. [14], αvβ3 was highly expressed on tumor cells in melanoma 
patients with lymph node and cutaneous metastasis, while microvessel densities (MVD) 
were low in those tumors.   
The αvβ3 receptors in the vascular space are readily available for Cy5.5-
c(KRGDf) targeting and for competitive binding with c(KRGDf) following i.v. 
administration.  On the other hand, the proportion of αvβ3 receptors on the cancer cells 
within the extravascular space may require longer time for extravasation, suggesting that 
early-time pharmacokinetics may not provide sufficient information on receptor 
availability on the M21 cancer cells.  Furthermore, extravascular receptors may not be 
adequately saturated by free c(KRGDf) after one hour and if they are, early time 
pharmacokinetics of Cy5.5-c(KRGDf) may again not be sufficient to report extravascular 
receptor availabilities.   
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While used by other investigators to assess specificity of targeting agents [40], we 
previously found that the TBR generally has large error bars and does not track changes 
in receptor availabilities as dynamic fluorescence imaging does as discussed in Section 3 
[8].  Specifically, the measurement of TBR is impacted by excitation light leakage 
through interference and holographic filters which can vary depending upon incident 
excitation illumination levels [78].  Nonetheless, we find that in the KS1767 tumor model, 
TBR is reduced with the pre-administration of c(KRGDf) as a competitive ligand one 
hour before administration of the imaging agent.  In contrast within the M21 model, pre-
administration of c(KRGDf) does not lead to a reduction in the TBR, consistent with 
extravascular expression of the αvβ3 target.  The results for early-time PK uptake 
parameter are consistent with TBR results.  In the KS1767 tumor model, the pre-
administration of c(KRGDf) prior to imaging agent administration reduces the uptake 
rate to levels that occur in the contralateral normal tissues while in the M21 tumor model, 
there is no significant difference.  Indeed, the uptake rates in M21 tissue ROIs are 
comparable to those in all contralateral normal tissue ROIs, suggesting that the 
availability of integrin receptors probed in early PK analysis in the M21 model is similar 
to that in normal tissues.    
While the early-time PK analyses may reflect the availability of vascular integrin 
receptors, the time delay between administration of c(KRGDf) as a competitive ligand 
and the imaging agent may also impact whether vascular or extravascular integrin 
receptors are accessible and the clearance rates of c(KRGDf).  For example, depending 
upon several factors (molecular size of competitive ligand and imaging agent, interstitial 
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pressure, and vessel permeability [90]) the time for saturation of extravascular integrin 
receptors following administration of competitive ligand may be longer than 1 hour.  
Indeed, using TBR analysis alone, it was noted that the blocking of αvβ3 integrin was the 
most effective 8 hours after the pre-administration of c(KRGDf) in M21 tumors. 
Vessel permeability may be an important feature to image in monitoring response 
to angiogenesis therapy.  EPR is a slow process, and significant uptake of targeting agent 
often needs several hours [91].  However, DeNardo et al. [92] showed that the αvβ3 
integrin may be a target for transiently increasing permeability of tumor vessels for 
increasing tumor uptake of radiolabeled monoclonal antibody (MAb) in 
radioimmunotherapy.  Cyclic RGD peptide (250 ug i.p.) provided 1 hr before 111-In-
ChL6 MAb∗ resulted in a 40 to 50 % increase in tumor uptake, when compared to the 
control tumor uptake, of MAb 24 hr after administration.  When cyclic RGD peptide was 
given as a continuous infusion (17.5 ug/hr) for 1 or 24 hr before 111-In-ChL6, tumor 
uptake of targeting agent was increased less.  In KS1767 xenograft model, we found that 
the TBR from images acquired at 10 min after the injection of a 3 nmol dose of Cy5.5-
c(KRGDf) with pre-administration of 600 nmol of c(KRGDf) was higher than that 
resulting from 300 nmol of c(KRGDf) (p<0.05), possibly indicating non-specific binding 
due to increased permeability (Figure 5.3(a)), since the early uptake parameters are not 
different.  The higher fluorescence intensity in tumor ROI may result from transiently 
increased permeability due to the apoptosis of endothelial cells.  
                                                 
∗ ChL6: a mouse-human chimeric antibody in which a mouse constant domains of murine L6 were 
substituted with human IgG1 constant domains 
  
 
78
 As pointed out in the introduction, dynamic imaging of integrin receptors is 
clinically relevant, since action of integrin based therapies differs depending upon the 
location of the integrin receptor, i.e., anti-angiogenesis in the vascular space or direct 
cytotoxicity to cancer cells in the extravascular space.  The investigation of therapeutic 
effects of integrin based therapy may not be fully understood from xenograft studies 
owing to host-cell interaction.  Consequently, the staging of integrin therapy used as an 
adjuvant to chemotherapy or radiation [93] depends upon understanding the modes of 
interaction and the tissue compartment of the disease marker used as a therapeutic target.  
With the conjugation of integrin targeting moieties with near-infrared dyes, the 
opportunity to diagnostically monitor response to therapy in skin and superficial vascular 
cancers such as melanoma and Kaposi’s sarcoma with dynamic fluorescence imaging is 
directly possible. 
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6. COMPARISON OF IN VIVO FLUORESCENCE IMAGING WITH NEAR 
INFRARED AND RED LIGHT EXCITABLE FLUORESCENT CONTRAST 
AGENTS  
 In Sections 4 and 5, PK analysis of dynamic CW fluorescence imaging was used 
to evaluate the uptake of a novel targeting agent, Cy5.5-c(KRGDf) into integrin αvβ3 
positive tumors.  Typically, free Cy5.5 in phosphate buffered saline is excited at 673 nm 
and the resulting fluorescence is collected at 692 nm [94].  In this thesis a 660 nm laser 
diode was used to excite Cy5.5 and a bandpass filter of 710 nm to transmit fluorescence 
emission was employed to provide a sufficient Stokes shift.  However, there is significant 
autofluorescence in background tissues at red light (~700 nm) excitation which can 
significantly decrease the target to background ratio in whole body imaging [41].  
IRDye800 or Indocyanine green (ICG) as a NIR dyes are excited at 785 nm and the 
emitted fluorescence collected at 830 nm.  The use of NIR excitable fluorescent dyes 
reduces autofluorescence and promotes deep tissue penetration for preclinical, small 
animal imaging, and should do the same in future clinical trials.  
The work presented in this section was performed as part of a collaborative effort.  
Animal care and preparation of fluorescent contrast agents were performed by our 
collaborators at Baylor College of Medicine who are recognized in the Acknowledgments 
of this thesis, while the fluorescence imaging and data analysis were performed entirely 
by the author. The experimental studies in this section compared whole animal 
fluorescence imaging with NIR and red light excitable fluorescent dyes.  
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6.1 Introduction 
 The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein 
that contributes to the regulation of cell growth, differentiation, apoptosis, and 
angiogenesis.  EGFR is overexpressed in many solid tumors as summarized in Table 6.1, 
resulting in tumor angiogenesis and tumor growth.  Therefore the detection of EGFR may 
help to determine an optimal strategy for cancer treatment.  Most EGFR imaging has 
been performed using nuclear imaging as described in Table 6.2.  Targeting agents such 
as antibodies against EGFR and its natural ligand, epidermal growth factor (EGF), have 
been labeled with a number of radionuclides.  These studies showed that tumor 
visualization as well as TBR depended upon the sizes of the targeting agents. For 
example, although tumors were easily visualized with radiolabeled antibody (more than 4 
hr after initial administration of radiolabeled agents), higher TBRs were observed with 
radionuclide labeled EGF [95, 96]. 
 
Table 6.1 EGFR density for A431, MDA-MB-468, MDA-MB-231, JW-97, MCF-7, 
C6EGFR glioma, and Normal hepatocytes tumor cells. 
 
Tumor cell line Number of receptors per cell 
A431 2 x 106 [97] 
MDA-MB-468 3 x 105 [97]; 1.3 x 106 [95] 
MDA-MB-231 1.3 x 105 [95] 
JW-97 2.7 x 105 [95] 
MCF-7 5 x 103 [97]; 1.5 x 104 [95] 
C6EGFR glioma 105 x 106 [98] 
Normal hepatocytes 8 x 104 to 3 x 105 [95] 
  
 
Table 6.2 Imaging of epidermal growth factor (EGFR) or EGFR tyrosine-kinase. 
 
 
Imaging 
modality and 
agent 
Dosage for 
imaging 
Imaging 
period 
Animal 
model and 
Cell line 
Targeting 
location Tumor uptake comments 
Ortu et al.  
[99] 
PET 
Irreversible 
inhibitors of 
[11C]ML03 
i.v., 100-200 
µCi 
1 hr after 
injection of 
agent 
rats 
A431 EGFr-TK
0.09 %id/g 15 min after 
injection 
Low accumulation of [11C]ML03 in the 
tumor and non specific binding in 
blocking study  
Bonasera et 
al.  
PET 
Reversible 
inhibitors of 
18[F]1 and 
18[F]4 
i.v., 10-20 
µCi 
1 hr after 
injection of 
agent 
mouse 
A431 EGFr-TK
18[F]1: 1.34 %id/g 1 hr 
after injection; 18[F]4: 
2.83 %id/g 10 min after 
injection 
Blocking time point is 10 min, but no 
decrease in radioactivity 
Goldenberg 
et al.  [97] 
Gamma-
camera 
imaging 
111In-DTPA-
C225 MAb  
and 111In-
DTPA-
KS1/4S-1 
i.p., 230 µg 
(290 µCi) to 
A431 and 85 
µg (105 µCi) 
to MDA-MB-
436 
xenografts 
3 and 6 
days after 
injection 
mouse 
A431, MDA-
MB-468, and 
MCF-7 
EGFR 
For A431 xenografts, 
28 %id/g and 
12.4 %id/g 3 and 7 days 
after injection, 
respectively; for MDA-
MB-468 xenografts, 
4.2 %id/g 8 days after 
injection 
Localization of imaging agents depended 
on EGFR expression and non-specific 
binding was also shown 
Divgi et al. 
[100] 
Gamma-
camera 
imaging and 
SPECT 
111In-DTPA-
MAb 225 
Infusion, 
Ranging from 
4 to 300 mg 
of labeled 
MAb 
three days 
after 
injection 
human (phase 
I) 
Patients with 
squamous cell 
lung cancer 
EGFR 
3.4 %id/g 72 hrs after 
injection of 120 mg of 
labeled MAb 
Toxicity was not observed when patients 
received up to 300 mg of MAb, and 
primary tumor could be imaged at doses 
of 20 mg or greater in dose-dependent 
manner 
Wen [101] 
Gamma-
camera 
imaging 
111In-DTPA-
PEG-C225 
and 111In-
DTPA-C225 
i.v., 10 µg; for 
blocking: 1 
mg of C225 
30 mins or 20 
hrs before 10 
µg of imaging 
agent 
up to 48 
hrs, 
however 
radioactivit
y in tumors 
reached at 
24 hrs after 
injection 
mouse 
MDA-MB-
468, MDA-
MB-435, and 
A431 
EGFR 
1:30 111In-DTPA-PEG-
C225: 8.68 %id/g; 1 mg 
of C225 30 min before 
injection of 111In-
DTPA-PEG-C225: 
13.85 %id/g 
Imaging agent reduced the non specific 
liver uptake, which resulted in improved 
tumor visualization, while tumor uptake 
of radiotracer was not significantly 
reduced after pre-injection of C225 
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Table 6.2 Continued. 
 
 
Imaging 
modality and 
agent 
Dosage for 
imaging 
Imaging 
period 
Animal 
model and 
Cell line 
Targeting 
location Tumor uptake comments 
Schechter 
[102] 
SPECT 
99mTc-EC-
C225 and 
99mTc-EC 
i.v., 0.05mg 
(22 mCi) to 
human; 10 10 
µg to rat 
for 
biodistribut
ion: 4 hrs; 
for 
imaging: 6 
hrs 
mouse, rat, 
and human 
For mouse 
and human: 
A431; for rat: 
13762NF; for 
human: 
EGFR 
With 99mcTc-EC-C225 
and 99mcTc-EC in 
113762NF, 0.416 %id/g 
and 0.342 %id/g 30 min 
after injection, 
respectively 
Biodistribution showed that tumor uptake 
of 99mcTc-EC-C225 was highest 30min 
after injection of imaging agent, and 
primary tumor but not nodal sites was 
visualized at 2 hr post-injection of 
imaging agent 
Meenakshi 
[103] 
Gamma 
camera 
imaging 
99mTc-
CIBCNSH3 
i.v., 200 µCi up to 24 hrs
mouse 
A431 and 
SUDHLH 
EGFR 
For A431 and 
SUDHLH, 12.15 and  
0.2 %id/g 24 hr after 
injection 
The results showed specific selective 
uptake of their agent by tumor with low 
uptake in other organs 
Iznage-
Escobar 
[104] 
Gamma 
camera 
imaging 
99mTc-moAb 
ior egf/r3 
i.v., 
30.3±11.9mCi 
(1 mg MAb) 
and 39.5 
±1.1mCi (3 
mg MAb) 
Up to 24 hr
human 
(phase I/II) 
Epithelial 
derived 
tumors 
EGFR N/A 
Binding of imaging agent was dose-
independent and that there was rapid 
clearance of radioactivity by renal and 
hepatobiliary excretion (87 %) 3 hr after 
injection of their agent 
Ramos-
Suzarte 
[105] 
Gamma 
camera 
imaging and 
SPECT 
99mTc-moAb 
ior egf/r3 
i.v., 3 mg 
(50mCi, 1.85 
GBq) 
up to 24 hrs 
for gamma 
camera; 5 
hrs after 
injection 
human 
(phase I/II) 
Epithelial 
derived 
tumors 
EGFR N/A 
Detected primary tumors as well as 
metastases with low amounts of imaging 
agents 
Onn [106] CT  N/A N/A 
human (72 
patients) 
stage I non-
small cell 
lung cancer 
(NSCLC) 
EGFR 
and 
HER2 
N/A 
EGFR overexpression and cavitation in 
squamous cell carcinoma was found more 
than that in adenocarcinoma, and patients 
with NSCLC with cavitation had a worse 
prognosis 
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Imaging 
modality and 
agent 
Dosage for 
imaging 
Imaging 
period 
Animal 
model and 
Cell line 
Targeting 
location Tumor uptake comments 
Abdel-Nabi 
[107] 
CT and 
SPECT 
111In-CYT 
103 
i.v. infusion, 
4.1 mCi (152 
MBq) of 111In-
CYT 103 at 
doses of 0.5 to 
20 mg 
2 to 7 days 
after 
infusion of 
imaging 
agent 
human (28 
patients, 
phase I/II) 
Colorectal 
carcinoma 
EGFR N/A 
Tumor was detected at doses of 1 mg or 
higher, and pre-administration of 18 mg of 
unlabeled CYT 103 1 hr before injection of 
2 mg of imaging agent did not cause a 
decrease in radioactivity uptake in normal 
liver tissue 
Yang [98] 
Gamma 
camera 
imaging 
99mTc-EGF 
i.c. or i.v., 31 
to 43 µCi (1.7 
to 2.3 µg) 
4 and 24 hr 
after 
injection 
rat 
EGFR gene 
transfected  
C6 rat glioma 
and C6 
wildtype 
tumor 
EGFR 
From biodistribution, 0.34 
and 0.45 %id/g 4 hr after 
i.c. injection with and 
without BBB-D, 
respectively, and 
0.14 %id/g 4 hr after i.v. 
injection; from gamma 
scintigraphic images,  1.73, 
2.80, and 2.94 counts/pixel 
4 hr after i.v., i.c., and i.c. 
with BBB-D injection, 
respectively. 
For brain tumor model, they showed i.c. 
injection is better than i.v. injection, but 
hperosmotic BBB-D did not improve 
tumor uptake of their imaging agent 
Rusckowski 
[96] 
Gamma 
camera 
imaging and 
autoradiogra
phy 
99mTc-EGF, 
99mTc-anti-
EGFR IgG, 
and 99mcTc-
BPTI 
i.v., 34-50 µg 
(300 µCi) for 
99mcTc-EGF; 8 
µg (200 µCi) 
for 99mcTc-anti-
EGFR IgG; 
200 µg of 
unlabeled EGF 
4 hr before 
injection of 
99mcTc-EGF  
12 or 18 hr 
after 
injection 
mouse 
A431 and 
LS174T 
EGFR 
From biodistribution of 
99mcTc-EGF, 0.40 (A431), 
0.32 (LS174T), and 0.29 
(preadministration of 
unlabeled EGF 4 hr before 
injection to xenografts 
bearing A431) %id/g in 
tumor thigh 18 hr after 
injection; from 
biodistribution of 99mcTc-
anti-EGFR IgG, 0.65 %id/g 
18 hr after injection 
They showed that (i) more favorable tumor to 
normal tissue ratios with 99mcTc-EGF compared 
to 99mcTc-anti-EGFR IgG, (ii) similar 
accumulation of 99mcTc-EGF in both tumor 
models, although LS174T has lower expression 
of EGFR, and (iii) highest accumulation of 
99mcTc-EGF in the kidneys. In addition, they 
showed that there was no significant difference 
in the accumulation between 99mTc-EGF and 
99mTc-anti-EGFR IgG in tumor. 
Schatten 
[108] 
CT and US 
123I-EGF 
s.c. into web 
space of each 
foot, 370 
MBq/mg (50 
µg) 
Up to 24 hr 
after 
injection 
human (14  
patients with 
stage III/IV)
Advanced 
cervical 
cancer 
EGFR N/A 
CT and US confirmed nodal involvement 
for 4 and 2 patients of the 11 positive 123I-
EGF scan and target to non-target ratios 
were highest 6-8 hr after injection 
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Imaging 
modality and 
agent 
Dosage for 
imaging 
Imaging 
period 
Animal 
model and 
Cell line 
Targeting 
location Tumor uptake comments 
Reilly [95] 
Gamma 
camera 
imaging 
111In-DTPA-
MAb 528 
and 111In-
DTPA-hEGF 
i.v., 1.85-3.7 
MBq  111In-
DTPA-hEGF 
(0.5-1µg) or 
111In-DTPA-
MAb 528 (25-
50 µg) 
72 hr after 
injection 
mouse 
MCF-7, 
MDA-MB-
231, JW-97, 
and MDA-
MB-468 
EGFR 
2.2 and 0.4 %id/g  72 hr 
after injection of 111In-
DTPA-hEGF with and 
without co-
administration of 
unlabeled 500 µg hEGF, 
and 21.6 %id/g 24 hr 
after injection of 111In-
DTPA-MAb 528 
They showed that (i) tumors were more easily 
visualized with 111In-DTPA-MAb 528, while 
higher tumor to blood ratios were observed 
with the 111In-DTPA-hEGF, (ii) no direct 
quantitative relationship between the level of 
receptors measured in vitro and the level of 
tumor uptake in vivo was not found, and (iii) 
tumor uptake in vivo is mostly controlled by 
elimination rate from the blood than by the 
expression level of receptor on cells. 
Dadparvar 
[109] 
Gamma 
camera and 
SPECT 
111In-EGFR 
425, 111In-
Co17-1A, 
and 111In-
chloride 
i.v., 2 to 
2.2mCi 
24 and 48 
hr after 
injection 
Human (28 
patients) 
glioma 
EGFR N/A 
They showed that the uptake of 111In-
EGFR 425 did not correlate with 
prognostic significance. In addition, they 
showed non-specific binding of 111In-
Co17-1A and 111In-chloride, and low 
specificity of 111In-EGFR 425 in glioma 
Kalofonos 
[110] 
Gamma 
camera 
imaging 
131I-H17E2 
and 123I-
EGFR1 MAb 
10 mCi 
Up to 48 hr 
after 
injection 
Human (27 
patients) 
glioma 
EGFR 
and 
PLAP 
0.0009-0.0057 %id/g 
with specific antibody 
and 0.00018-
0.00465 %id/g with 
non-specific antibody 
They showed the localization of 131I-
H17E2 and 123I-EGFR1 MAb in glioma 
tumor region.  However, the difference in 
accumulation between specific and non-
specific antibody in the tumor was small.
Vallis [111] 
Gamma 
camera 
imaging and 
SPECT 
99mTc-hR3 
i.v., 3 or 6 mg 
(1010 MBq, 
27mCi) 
Up to 24 hr 
after 
injection 
Human (12 
patients) 
Epithelial 
derived 
carcinomas 
EGFR N/A 
They found that (i) immunocytochemical 
staining of tumor biopsies for EGFR 
positivity did not predict positive tumor 
imaging, (ii) the increase in circulating 
radioactivity due to catabolism of 99mcTc-
hR3 in tissue, and (iii) high accumulation 
in the liver and kidney, suggesting 
increasing the dosage of 99mcTc-hR3 
        
        
        
84
  
 
Table 6.2 Continued. 
 
 
Imaging 
modality and 
agent 
Dosage for 
imaging 
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model and 
Cell line 
Targeting 
location Tumor uptake comments 
Lee et al. 
[112] 
Gamma 
camera, 111In-
native 528 
MAb, 111In-
cationized 528 
MAb, and 
111In-PEG-
cationized 528 
MAb 
i.v., 50 µCi 24 hr after injection 
mouse 
U87 EGFR N/A 
They showed that the pegylation did not 
reverse the serum inhibition of the 
cationic charge on the MAb and that that
radiolabeling a cationized MAb with 
DTPA produces a serum neutralization of 
the initial cationization 
modification 
Cornelissen 
[113] 
Gamma 
camera 
imaging 
99mTc-
HYNIC-
hEGF 
i.v., 3.7 MBq 
(1 µg) for 
imaging; 100 
µg of 
unlabeled 
hEGF for 
displacement 
experiment 
2 hr after 
injection 
mouse 
LoVo cells 
EGFR: 
for 
response 
to 
farnesyltr
ansferase 
inhibitor 
(FTI) 
therapy 
TBRs were 1.1 and 2.5 
at 2 hr post-injection of 
99mTc-HYNIC-hEGF 
with or without 
unlabeled hEGF, 
respectively; TBRs for 
untreated animals with 
FTI and 6 hr after 
administration of FTI 
were 2.6 and 1.1, 
respectively 
They showed that (i) coinjection of 
unlabeled hEGF and blocking with 
MAb88910 decreased the tumor to 
normal tissue ratios to 1.1 and 1.2, 
respectively. In addition, they showed 
therapy response of FTI inhibitor, e.g., 
100 mg/kg R115777 
Vinter-
Jensen 
[114] 
Gamma 
camera 
imaging 
131I-EGF 
Jugular i.v., 
10 nmol (3.4-
4.7 MBq/kg)
2 hr after 
injection pig EGFR N/A 
The uptake in the liver was the highest at 
6-8 min after injection and remained at a 
plateau for 10 min before it declined. The 
time activity curve in the kidneys peaked 
after 3-5 min with a short plateau, and 
then declined 
Ke [115] 
Optical 
imaging 
Cy5.5-EGF, 
ICG, and 
Cy5.5 
1 nmol of ICG , 
2.9 nmol of 
Cy5.5, 1 nmol 
of  EGF-Cy5.5 , 
and blocking 
study, 1.9 mg 
of C225 (12.7 
nmol) 
up to 192 
hr after 
injection of 
imaging 
agent 
mouse 
MDA-MB-
468 and 
MDA-MB-
435 
EGFR N/A 
They showed that ICG and Cy5.5 did not 
bind to both tumors, while Cy5.5-EGF 
accumulated only in MDA-MB-468 
tumors. Tumor uptake of Cy5.5-EGF was 
blocked by C225.  
 
85
  
86
 There are no correlation between in the imaging agents and the in vitro receptor 
densities [95].  It may indicate that tumor uptake in vivo is mostly controlled by 
elimination rate of imaging agents from the blood than by the expression level of receptor 
on cells.  Recently, polyethylene glycol (PEG) as a linker between monoclonal antibody 
against EGFR and chelator has been employed to reduce liver uptake, which resulted in 
improved detection of EGFR-positive tumors [101].   
Most standard nuclear imaging studies have shown static images, including 
information about tracer distribution and receptor densities.  Recently EGFR positive 
tumors were visualized in whole body fluorescence imaging using Cy5.5 conjugated with 
EGF [115].  They showed dynamic measurement of fluorescence intensities for the first 
20 min after tail vein injection.  With high sensitivity and sub-second camera exposure 
time, dynamic whole-body imaging should be useful to differentiate tumors from normal 
tissue regions, and to monitor the real-time distribution of the imaging agents.  In the 
studies, there was significant autofluorescence at 660 nm excitation, which can 
significantly decrease TBR and may reduce the image quality as previously discussed.  
Reducing the background autofluorescence should enhance the TBR, improving tumor 
detection and providing more information about therapeutic efficacy and tumor 
physiology during the uptake and washout phases.  In order to investigate the impact of 
autofluorescence during dynamic imaging, we labeled EGF with two fluorescent dyes, a 
near-infrared fluorescence dye, IRDy800, and a red light excitable fluorescence dye, 
Cy5.5.  Fluorescence images of each animal were compared before and after injection of 
either the NIR or the red fluorescent conjugate.  We qualitatively compared the 
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background signals of an animal positioned next to a vial filled with 10 pmol of each 
fluorescent conjugate in 200 µl of normal saline. 
 
6.2 Materials and Methods 
6.2.1 Tumor Cell Lines and Animal Models 
 Human breast cancer cell line MDA-MB-468, positive for the epidermal growth 
factor receptor (EGFR), was purchased from American Type Culture Collection 
(Manassas, VA).  The cells were cultured in DMEM/F12 (Invitrogen, Carlsbad, CA) with 
10% FBS (Hyclone, Logan, UT) in a humidified incubator maintained at 37oC with 5% 
CO2.  Four week old nude mice were purchased from Harlan (Indianapolis, IN).  When 
the MDA-MB-468 cells reached 95% confluence, they were treated with trypsin, washed 
with PBS, and resuspended at 1x106 cells per 100 µl PBS.  Each mouse was injected 
subcutaneously with 1x106 cells in the right flank.  Palpable tumors of size 4 to 6 mm in 
diameter developed within 3 to 4 weeks. 
 
6.2.2 Fluorescent Dye Conjugates 
 Epidermal growth factor (EGF) from mouse submaxillary glands was purchased 
from Invitrogen (Carlsbad, CA) and resuspended at 200 µg/ml in 0.1M sodium 
bicarbonate buffer pH 8.5.  Cy5.5-NHS ester was obtained from GE Healthcare, formerly 
Amersham Pharmacia Biotech, (Piscataway, NJ) and resuspended in DMSO at 10mg/ml.  
IR800-NHS ester was obtained from Licor Biosciences (Lincon, NE) and resuspended in 
Methanol at 10mg/ml.  EGF was reacted with Cy5.5-NHS or IR800-NHS in a 1:5 protein 
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to dye molar ratio for 1 hour at room temperature with shaking.  Free dye was removed 
by size exclusion chromatography on a 10DG desalting column (Biorad, Hercules, CA). 
 
6.2.3 Fluorescence Imaging System 
 A laser diode of 785 nm for IRDye800 excitation was added to the dynamic 
fluorescence optical imaging system described in Section 3.  Both laser diode excitation 
sources (785-nm, 85-mW for IRDye800; 660-nm, 35-mW for Cy5.5) were operated at 85 
mA for IRDye800 and 65 mA for Cy5.5, and expanded uniformly with a plano-convex 
lens and diffuser to approximately 8-cm diameter area for illumination of the whole body 
of a mouse.  A holographic notch-plus band-rejection filter (660-nm center wavelength 
for Cy5.5, OD at λx reported to be > 6, 785-nm center wavelength for IRDye800, OD at 
λx reported to be > 6; Kaiser Optical Systems Inc., Ann Arbor, MI) and a bandpass filter 
(830-nm center wavelength for IRDy800, OD at λx reported to be > 4, 710-nm center 
wavelength for Cy5.5 OD at λx reported to be 3; CVI Laser Corporation, Albuquerque, 
NM) were fitted with the 50-mm lens to reject back-scattered and reflected excitation 
light and select fluorescence emission light.  White light images were taken with a low-
power lamp after all filters were removed. 
 
6.2.4 In vivo Fluorescence Imaging 
 Before administration of the imaging agent, animals were placed on a 
temperature-controlled heat pad (Spin System, Australia) at 37 C under isofluorane 
anesthesia (VetEquip, Pleasanton, CA and IsoSol Isofluorane USP, VEDCO Inc., St. 
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Joseph, MO) and a catheter was inserted into the tail vein. All fluorescent images were 
acquired with 800 msec integration time, so the intensities from each image could be 
compared during analysis [8].  Intensifier gain was varied from 40% of the maximum 
gain for white light images to 95% of the maximum gain for fluorescence images.  After 
taking white light images, 0.2 ml of either Cy5.5-EGF or IRDye800-EGF (1 nmol 
equivalent Cy5.5 and IRDye800 per mouse) was injected via the tail vein catheter.  Two 
groups of control mice received 0.2 ml of Cy5.5 (1 nmol per mouse) and IRDye800 (1 
nmol per mouse).  In addition, one group of mice was pre-administered with C225, an 
EGFR antibody, at a dose of 1.9 mg (12.7 nmol per mouse) 24 hr before injection of 0.2 
ml of IRDye800-EGF (1 nmol per mouse).  Fluorescence images were obtained every 1.1 
seconds for approximately 40 min with IRDye800, IRDye800-EGF, and IRDye800-EGF 
with pre-administration of C225 and 20 min with Cy5.5 and Cy5.5-EGF.  Fluorescence 
images were taken up to 48 hr following initial injection of contrast agent.  Six 
fluorescence images serve as “background” images prior to bolus administration of the 
imaging agent.  Additionally, fluorescence images of an unmanipulated animal next to a 
vial containing 10 pmol of either Cy5.5-EGF or IRDye800-EGF in 200 µl of normal 
saline was taken to quantitatively measure autofluorescence background.  
 
6.2.5 Data Processing and Statistics 
 After acquiring the images with V++ software (Digital Optics, Auckland, New 
Zealand), data analysis and processing were accomplished by Matlab software (The 
MathWorks, Inc., Natick, MA), SigmaPlot software package (SPSS Inc., Chicago, IL), 
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and ImageJ (National Institutes of Health, Washington, DC).  Using white light images, 
two regions of interest (ROI), (i) the tumor for target ROI and (ii) the contralateral 
normal tissue region for background ROI, were defined, each having the same numerical 
surface area.  The mean fluorescence intensity for each ROI in each fluorescence image 
was plotted as a function of time.  TBR was calculated by dividing the mean intensity in 
the tumor ROI by that in the contralateral normal ROI.  In addition, using fluorescence 
images, the chest, kidney, and head regions were defined as target ROIs, and the stomach 
as the background ROI.  The statistical analysis was performed with SPSS 12.0.1 
statistical program (SPSS, Inc., Chicago, Illinois).  The differences were considered 
significant at p < 0.05. 
 
6.3 Results 
6.3.1 Autofluorescence 
 Figure 6.1 illustrates side by side comparison of conjugate free, unmanipulated 
animals illuminated with 660 nm (Figure 6.1 (a)) and 785 nm (Figure 6.1 (b)) light with a 
vial of 10 pmol of either EGF-IRDye800 or EGF-Cy5.5 for reference.  The 
autofluorescence signals in NIR image (Figure 6.1 (b)) are significantly lower than from 
red fluorescent dye (Figure 6.1 (a)). 
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Cy5.5-EGF IRDye800-EGF
(a) (b)
 
Figure 6.1 Comparison of autofluorescence in two different dye conjugates.  Mice that 
have not been injected with any dye are next to a tube containing 10 pmol of Cy5.5-EGF 
(a) or IRDye800-EGF (b) in 200 µl of saline.   
 
 
6.3.2 Dynamic Fluorescence Intensity vs. Time Profiles 
 Figure 6.2 displays an example of the normalized fluorescence intensities as a 
function of time from MDA-MB-468 tumor and contralateral normal tissue ROIs for 40 
min after administration of IRDye800-EGF, IRDye800, and IRDye800-EGF 24 hr after 
injection of C225, and 20 min after administration of Cy5.5-EGF and Cy5.5.  The tumor 
sizes in all animals studied in this experiment are ~ 6 mm in diameter, except one animal 
(12 mm in diameter), shown in Figure 6.2 (b).  Figure 6.2 shows that the fluorescence 
intensities in the tumor ROIs increased more quickly than those in normal tissue ROIs 
after injection of IRDye800-EGF (Figure 6.2 (a) and (b)) and Cy5.5-EGF (Figure 6.2 (e)). 
The intensities in the tumor ROIs of mice injected with IRDye800 continually increased 
for 21 min, plateaued for 10 min, and then decreased to that of normal tissue ROIs as 
shown in Figure 6.2 (c). 
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Figure 6.2 Normalized fluorescence intensity vs. time profiles from xenografts of MDA-
MB-468 that received an injection of the (a) and (b) IRDye800-EGF, (c) IRDye800, (d) 
IRDye800-EGF 24 hr after administration of C225, (e) Cy5.5-EGF, and (f) Cy5.5 at 1 
nmol in 200 µl of normal saline, acquired from the tumor (black) and normal (gray) ROIs. 
 
  
93
 In mice injected with Cy5.5, the fluorescence intensities for tumor and normal 
tissue ROIs were similar (Figure 6.2 (f)).  In mice pre-administered with C225, the 
normalized fluorescence intensities from the tumor ROIs were reduced (Figure 6.2 (d)).  
The fluorescence intensities in tumor and normal tissue ROIs from MDA-MB-468 
xenograft bearing mice after injection of Cy5.5-EGF or Cy5.5 were similar to our 
previous results [115].  A bolus peak in the fluorescence intensity profiles around 5.5 sec 
after injection of IRDye800-EGF or Cy5.5-EGF is also shown in Figure 6.2.  
 
6.3.3 In vivo Fluorescence Imaging 
 Due to the sensitivity of our home-built fluorescence imaging system, we can 
image real-time circulation of small quantities of fluorescent conjugates throughout a live 
mouse.  Figure 6.3 shows posterior white light and fluorescence images from one 
representative of each experimental group, displayed every 1.1 seconds for a period of 
approximately 7.7 seconds following initial injection of IRDye800 (first column), 
IRDye800-EGF administered without (second column) or with (third column) C225, and 
Cy5.5-EGF (forth column).  All fluorescence images are illustrated on the same linear 
color scale to allow for a direct qualitative comparison.  There was no autofluorescence 
from animals before injection of NIR fluoresce at 785 nm excitation as shown in Figure 
6.3.  There was, however, autofluorescence in stomach and gastrointestinal regions at 660 
nm excitation before injection of red light excitable dyes.   
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Figure 6.3 Dynamic fluorescence images immediately following injection of IRDye800 
(first column), IRDye800-EGF (second column), IRDye800-EGF 24 hr after 
administration of C225 (third column), and Cy5.5-EGF (fourth column) at 1 nmol in 200 
µl of normal saline for ~7.7 sec. C: chest, S: stomach, H: head, K: Kidney, and T: tumor. 
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 Immediately after injection of NIR fluorescence dyes via a tail vein catheter, 
fluorescence signal was detected from the tail.  Subsequently, the chest, kidneys, head 
regions were clearly seen with the interval of 1.1 sec.  Moreover, the tumor was detected 
from 4.4 sec after injection of IRDye800-EGF and IRDye800 as shown in Figure 6.3.  At 
7.7 seconds after initial injection of the conjugate the whole body of a mouse became 
bright.  In order to demonstrate the in vivo binding specificity of the IRDye800-EGF, 
fluorescence imaging was performed immediately after injection of 1 nmol dose of 
IRDye800-EGF but 24 hr after administration of 1.9 mg of native C225.  Figure 6.3 
shows that the tumor regions had little or no detectable fluorescence above the normal 
region after pre-administration of C225.  The fluorescence images from MDA-MB-468 
xenografts injected with Cy5.5-EGF showed limited ability to detect real-time spatial 
distribution of imaging agents due to the high level of autofluorescence as shown in 
Figure 6.3. 
 Figure 6.4 displays TBRs calculated using the animals’ chest, kidneys, and head 
areas as target ROIs, and dividing their mean fluorescence intensities by that of the 
stomach area, which was set as the background ROI.  The TBR values were computed at 
7.7 seconds after injection of 1 nmol (in 0.2 ml volume) of IRDye800-EGF and Cy5.5-
EGF (n=3 for each test group).  Figure 6.4 shows that all the time dependent TBR values 
from IRDye800-EGF injections were higher than those of Cy5.5-EGF, because of high 
background signals from the abdomen area at 660 nm excitation.   
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Figure 6.4 The ratio of head, chest, kidneys, and tumor ROIs to stomach background 
ROIs as a function of time in animals injected with 1 nmol of IRDye800-EGF (a) and 
Cy5.5-EGF (b) for 8 sec. Error bars represent the standard deviation. 
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 Fluorescence imaging was also conducted 24 and 48 hours after initial injection of 
imaging agent.  Fluorescence images of dissected organs from a xenograft bearing MDA-
MB-468 tumors 48 hr after injection of 1 nmol of IRDye800-EGF, IRDye800, and 
IRDye800-EGF 24 hr after administration of C225 are shown in Figure 6.5.  The tumor 
was detected from the fluorescence images after administration of IRDye800-EGF alone 
(Figure 6.5 (a) and (b)), while the tumor was not clearly detectable in fluorescence 
images 24 and 48 hr after injection of IRDye800 (Figure 6.5 (d) and (e)) and IRDye800-
EGF with pre-administration of 1.9 mg of native C225 (Figure 6.5 (g) and (h)).  In 
addition to the tumor from animals injected with IRDye800-EGF, the liver and kidneys 
also showed strong fluorescence signal (Figure 6.5 (c)).  The fluorescence signal 
originating from the liver, kidneys, and tumor in animals injected with IRDye800 (Figure 
6.5 (f)) or IRDye800-EGF 24 hr after administration of C225 (Figure 6.5 (i)) was 
significantly reduced. 
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Figure 6.5 Whole-body fluorescence images of animals at 24 and 48 hr after the 
administration of 1 nmol of IRDye800-EGF (first row), IRDye800 (second row), and 
IRDye800-EGF 24 hr after administration of C225 (third row), and fluorescence images 
of dissected organs from a xenograft bearing MDA-MB-468 tumor 48 hr after injection 
of contrast agents. H/L: heart/lung, LI: liver, S: spleen, K: kidney, M: muscle, T: tumor, 
and B: blood. 
 
 In mice injected with Cy5.5-EGF, the tumor was also detectable 24 hr after initial 
injection (Figure 6.6).  By removing the mouse skin around tumor and normal ROIs, a 
better image of the tumor with higher TBR (Figure 6.7) resulted due to reduced 
autofluorescence from the skin and increased fluorescence signal in the tumor ROI 
probably due to removal of signal attenuation in the skin (p<0.05).  
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Figure 6.6 Fluorescence images of animals with and without skin in tumor and normal 
ROIs 24 hours after the administration of 1 nmol of Cy5.5-EGF. 
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Figure 6.7 The ratio of tumor ROI to normal tissue ROI’s intensities from animals with 
and without skin in tumor and normal ROIs at 24 hr after injection of 1 nmol of Cy5.5-
EGF. The error bars represent the standard deviation and ☆ denotes the statistical 
significance. 
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 Figure 6.8 shows the TBR for three groups of animals after the injection of 
IRDye800, IRDye800-EGF, and IRDye800-EGF after pre-administration of C225 (n=3) 
at different time points after administration.  The background TBRs before administration 
of fluorescent agents were similar.  However, the TBR at 40 min and 24 hr after injection 
of IRDye800-EGF is statistically different from that of animals injected with IRDye800 
and IRDye800-EGF after injection of C225 (p<0.05).  
 
 
Figure 6.8 The ratio of the tumor to normal ROI intensities in MDA-MB-468 xenografts 
after injection of IRDye800-EGF (black column), IRDye800 (white column), and 
IRDye800-EGF with pre-administration of C225 antibody (gray column) at different time 
points. The points represent the mean value of the test group and the error bars the 
standard deviation. 
 
 
0
0.5
1
1.5
2
2.5
0 min 40 min 24 hr 48 hr
TB
R
IRDye800-EGF
IRDye800
C225, IRDye800-EGF
  
101
6.4 Discussion 
 In this study, we demonstrated the advantages of dynamic fluorescence imaging 
to determine the spatial distribution of small quantities of NIR fluorescent contrast agents 
through the whole body of xenografts bearing MDA-MB-468 tumors for a short period of 
time.  Dynamic imaging using targeting or non-specific agents has the potential for the 
study of delineation between normal and diseased tissues and of transient disease marker 
expression in tumor physiology resulting from cancer treatment.  In addition, dynamic 
imaging might help screen drugs and optimize treatment procedure.  Berard et al. [116] 
demonstrated dynamic PET imaging collecting one image every 60 sec for 2 hr to 
monitor transient metabolic processes and to investigate the mechanisms of 
photosensitizing drugs in the photo-dynamic therapy (PDT) of cancer.  The 18F-FDG 
time–activity curves showed distinct transient patterns during PDT.  In our dynamic 
fluorescence imaging, the CCD exposure time is 800 msec, which enables near real-time 
in vivo fluorescence imaging.  As shown in Figure 6.2, dynamic measurement of 
fluorescence intensities clearly showed different uptake in the first 40 min after injection 
of contrast agents.  The rates of uptake of IRDye800-EGF and Cy5.5-EGF were 
significantly greater and faster in tumor ROIs than in contralateral normal tissue ROIs.  
However, the signals in tumor ROIs in animals injected with IRDye800 and IRDye800-
EGF with pre-administration of CC5 antibody were similar to those in normal tissue 
ROIs. 
Dynamic fluorescence imaging can be used to differentiate animals with different 
tumor stages.  Fluorescence intensities in animals with larger tumors, i.e. > 12 mm in 
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diameter show higher peak at ~ 5.5 sec after initial injection of IRDye800-EGF (Figure 
6.2 (b)) and slower uptake as compared to smaller tumors, possibly due to vascular 
permeability difference and highly elevated IFP resulting from tumor mass.  Elevated IFP 
may reduce extravasation of the contrast agents causing the binding to occur over a 
longer time if the agent remains in circulation.  Fluorescence intensities in tumor ROIs 
after injection of non-specific agent, IRDye800, increased for 21 min, plateaued for 10 
min, and then decreased to the intensity level of normal tissue ROIs.  The relatively 
increased fluorescence intensities in tumor ROIs over normal ROIs in the same animal 
may also be due to increased permeability in the leaky vasculature in tumor regions.  
Vascular permeability increases in tumors, which facilitates leakage of i.v. administered 
drugs into the surrounding tissue.  Previously, it was reported that ICG and fluorescein 
angiograms could be used to assess cancerous regions due to different permeability levels 
[117-119].  However, fluorescence intensities did not differ between tumor and normal 
ROIs in mice injected with Cy5.5.  In mice injected with IRDye800-EGF 24 hr after 
administration of C225, the fluorescence intensity profiles between tumor and normal 
ROIs were similar, which might result from reduced availability of EGFR.   
Dynamic fluorescence images correlated well with the fluorescence intensity 
profiles.  There was little or no autofluorescence from animals before injection of 
IRDye800-EGF or IRDye800 at 785 nm excitation.  This enabled the detection of the 
spatial distribution of agent in the chest, head, and kidney regions every 1.1 sec 
immediately following a tail vein injection of NIR fluorescent agents as shown in Figure 
6.3.  The liver and bladder were also detected from anterior view.  Interestingly, the 
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tumor was readily detected around 4.4 sec after injection of IRDye800-EGF and 
IRDye800 (Figure 6.3) at the same time the bolus peak in fluorescence intensities 
appeared in Figure 6.2.  However, tumors were not detected in images of animals bearing 
MDA-MB-468 injected with IRDye800-EGF 24 hr after pre-administration of C225.  Not 
yet proven, we hypothesize that tumor detection after administration of IRDye800-EGF 
and IRDye800 mainly resulted from increased permeability in tumor vasculature 
allowing dye entry into the tumor.  Therefore, no visualization of tumors after pre-
administration of C225 might result from decreased permeability and reduced availability 
of EGFR, indicating C225 as an anti-angiogenic therapeutic agent.  Similarly, Izumi et al. 
[120] demonstrated that tumor blood vessels after herceptin (antibody against EGFR-2) 
treatment resemble a normal phenotype, resulting in reduced vascular permeability in 
tumor vasculature.  In addition, C225 has been used to treat EGFR negative colorectal 
cancer patients [121], indicating the role of C225 as indirect anti-angiogenic therapeutics.  
Although it is difficult to verify whether tumor detection is only due to increased 
permeability or binding of the agent to EGFR, for a short time after injection of the 
contrast agents, dynamic fluorescence imaging may provide more quantitative 
information using PK models [8]. 
For red light excitable fluorescent dyes, Cy5.5-EGF autofluorescence at 660 nm 
increased the background signals deteriorating the image quality during dynamic imaging 
(Figure 6.3).  The level of autofluorescence light from excitation at 660 nm & emission at 
710 nm was greater than that of 10 pmol of Cy5.5-EGF (Figure 6.1).  Therefore, an 
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adequate dose for molecular dynamic imaging at this wavelength must be above the 
threshold, e.g., to overcome the background autofluorescence.   
Light generated by fluorescent imaging agents within tissue must propagate to the 
surface for collection through appropriate filters onto an area imaging device.  Three 
characteristics impact the sensitivity of imaging agents in vivo: (i) the camera/detection 
sensitivity [122], (ii) excitation light leakage [78], and (iii) background autofluorescence 
[122-124].  Our experiments show that the ICCD camera system can detect small 
quantities of fluorescent conjugates (1 nmol in this study) and dynamically images in 
near real-time using a sub-second exposure time.  In addition to the sensitive ICCD 
imaging system, the use of combined holographic and interference filter sets along with a 
narrow band illumination source, as used herein, reduced the out-of-band signal and the 
systematic noise level such as excitation light leakage [45].  Unfortunately, the 
background at 660 nm excitation is mainly due to autofluorescence.  Since the optical 
density (OD) of holographic filters to reject the excitation wavelength for both 
fluorophores is comparable, and the OD of the bandpass filter to select the emission 
wavelength is greater for Cy5.5 than IRDye800, there should be less light leakage 
through the Cy5.5 filters than the IRDye800 filters.  Troy et al. [122] showed quantitative 
analysis of autofluorescence signal, which resulted from tissue and instrumental 
autofluorescence.  They showed that an alfalfa-free diet combined with appropriate filter 
sets could lower the autofluorescence signal in the gastrointestinal regions.  In addition, 
fluorescence imaging with a spectral unmixing algorithm can further reduce the 
autofluorescence from endogenous chromophores up to far-red region of spectrum [125].   
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These findings suggest that dynamic planar optical imaging with reduced 
background can provide the spatial distribution of the fluorescence conjugates and 
sensitive detection of disease regions.  Furthermore, specifically targeted contrast agents 
may be more effective for diagnosing of solid tumors. 
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7. IMAGING THE LYMPH NETWORK AND αvβ3 RECEPTOR EXPRESSED 
IN XENOGRAFTS OF HUMAN KAPOSI’S SARCOMA 
In the previous sections we used single wavelength dynamic fluorescence imaging to 
detect only the tumor compartment.  In this section, we imaged two different tissue 
compartments, tumor vasculature and the draining lymph node, using dual-wavelength 
fluorescence imaging.  The ability to image both tumor blood vessels and lymph vessels 
will improve our understanding of disease progression. 
 
7.1 Introduction 
 Lymph node status serves as an important prognostic marker in breast cancer as 
well as several other cancers.  The sentinel lymph node (SLN) is the first lymph node on 
the lymphatic drainage pathway from the tumor site.  The underlying hypothesis of SLN 
mapping is that the first draining node will contain tumor cells if the cancer is metastatic.  
When the SLN is resected and found to be negative for metastatic cells, it is assumed that 
there are no other positive nodes and further lymph node dissection is not necessary. The 
introduction of a less invasive SLN mapping technique could minimize the number of 
lymph nodes resected which would preserve lymphatic function.   
 Traditionally, SLN mapping has been conducted by nuclear imaging with 99mTc 
[126-129]. The radiocolloid is often coupled with blue dye for visual surgical guidance 
after gamma scintigraphy to locate the sentinel node.  MRI [130, 131], CT [132], and 
PET [133-142] have also been used to detect lymphatics.  In this Section, we imaged 
lymph nodes in non-tumor bearing mice after intradermal (i.d.) injection of Cardiogreen.  
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In addition, we detected tumors after i.v. injection of targeted, cold 111-In-DTPA-
K(IRDye800)-c(KRGDf) and lymphatics after i.d. injection of non-specific red light 
excitable Cy5.5 in mice bearing human Kaposi’s sarcoma (KS SLK).  
 
7.2 Materials and Methods 
 Using a 34-gauge or 26-gauge needle, 9.6 nmol of Cardiogreen in 200 µl of saline 
was injected into the left rear limb for popliteal node imaging and into the right front limb 
of four to six week-old female normal nude mice for axillary node imaging.  A schematic 
diagram of the lymph node locations in mice is shown in Figure 7.1.  After 20 mins, 
fluorescence guided lymphadenectomy was performed using near real-time fluorescence 
images.  Histopathology was performed on the excised samples. 
Popliteal
 
Figure 7.1 Schematic of localization of lymph system [6]. 
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 A Kaposi’s sarcoma (KS SLK) xenograft tumor was used to image presence of 
αvβ3 integrin in tumor angiogenesis and lymphangiogenesis.  Mice were imaged 24 hrs 
after the i.v. injection of αvβ3 targeting cold 111-In-DTPA-K(IRDye800)-c(KRGDf), 
and then 5 nmol of Cy5.5 in 200 µl of saline was injected into the rear left mouse foot 
using 31-gauge needle for imaging lymph nodes.  Again, after 40 to 120 minutes, 
fluorescence guided lymphadenectomy was performed on tumor bearing mice. 
  Dual wavelength fluorescence imaging system was used in these studies.  A laser 
diode (80 mW, 785-nm for near-infrared (NIR) dyes and 35 mW, 660-nm for Cy5.5 
excitation) provided excitation light, which uniformly illuminated the whole body of the 
mouse through a convex lens and diffuser.  To reject backscattered and reflected 
excitation light, a holographic notch-plus band rejection filter (780-nm center wavelength 
for NIR dyes and 660-nm center wavelength for Cy5.5) and a bandpass filter (830-nm 
center wavelength for NIR dyes and 710-nm center wavelength for Cy5.5) were 
positioned prior to a 28-mm Nikon lens (Nikon, Japan).  The re-emitted fluorescent light 
was detected by an electron-multiplying charge-coupled device (EMCCD) camera.  All 
the fluorescence images acquired in this study were taken with an 800 msec CCD 
integration time, by a personal computer running V++ imaging software. 
 
7.3 Results 
 Figure 7.2 shows that the left popliteal node and the liver were visible 5 mins after 
the injection using 34-gauge needle, and the secondary node, mesenteric lymph node near 
G.I. tract was detected at 20 mins after the initial injection. A fluorescence guided 
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lymphadenectomy was performed by covering liver region to increase the signal intensity 
of mesenteric lymph node.  Both popliteal and mesenteric nodes were successfully 
removed as presented in Figure 7.2. Successful excision of lymph nodes through image-
guided surgery was verified by histology as shown in Figure 7.3.   
 
 
Figure 7.2 Dynamic NIR fluorescence images of a healthy mouse injected into the left 
mouse foot with 9.6 nmol of Cardiogreen in 200 µl of saline.  Popliteal and secondary 
mesenteric nodes were successfully imaged, and thus removed through image-guided 
surgery. 
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Figure 7.3 Histopathology of muscle, and mesenteric and popliteal nodes from real-time 
NIR image-guided lymphadenectomy.  
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 Figure 7.3 shows the histopathology results from the excised muscle, and 
mesenteric and popliteal nodes, which confirm the location of lymph nodes and the 
successful removal achived through image-guided surgery.  Figure 7.4 shows 
fluorescence images after i.d. injection of 5 nmol of cardiogreen in 200 µl of saline into 
the right mouse paw using 26-gauge needle.  After covering the injection site, the axillary 
lymph node was clearly detected and the liver was fluorescent 10 min after injection.  
The fluorescence signal in axillary lymph node started decreasing 1 hr after injection, 
possibly due to drainage of the contrast agent into a deeper location. 
 
Figure 7.4 NIR Fluorescence images in a healthy animal injected into the right front limb 
with 5 nmol of Cardiogreen in 200 µl of saline.  The axillary lymph node was detected up 
to 3 hrs after initial injection of Cardiogreen. The arrow head and arrow indicate injection 
site and the location of lymph node, respectively. 
 
10 min 20 min
2 hr1 hr30 min
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 Fluorescence images were also acquired in a KS SLK xenograft model using 660 
nm excitation and 710 nm collection optics after injection of 5 nmol of Cy5.5 in 200 µl of 
saline.  As shown in Figure 7.5, the popliteal node was detected 5 min after i.d. injection 
of Cy5.5 using 31-gauge needle.   Due to high autofluorescence signal, however, the 
secondary mesenteric node, as shown previously in Figure 7.2 could not be differentiated 
from G.I. tract.  From the posterior view, fluorescence signal around the tumor region, 
which may result from a lymphatic vessel, was detected 10 mins after the injection of 
Cy5.5 and seen for up to 2 hrs after injection. 
 
Figure 7.5 Dynamic fluorescence images acquired from a xenograft bearing KS SLK 
using 660 nm excitation and 710 nm collection optics for Cy5.5 after injection of 5 nmol 
of Cy5.5 in 200 µl of saline. The arrow indicates the location of lymphatics in tumor 
region. 
5 min
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 Additionally, dual-wavelength fluorescence imaging was conducted in mice with 
KS SLK tumors and the excised organs using (i) 785 nm excitation illumination and 830 
nm collection optics for cold 111In-DTPA-K(IRDye800)-c(KRGDf) and (ii) 660 nm 
excitation and 710 nm collection optics for Cy5.5.  Fluorescent imaging occurred 24 hrs 
following the initial i.v. injection of cold 111In-DTPA-K(IRDye800)-c(KRGDf).  Then, 
Cy5.5 was injected intradermally into the rear left mouse limb using 31-gauge needle.  
After 40 minutes, the popliteal node was visible and again removed through image-
guided surgery.  The removed node is shown in Figure 7.6.  
White light IRdye800 Cy5.5 Overlaid 
tumor
H/L
Liver Spleen
Kidney
Muscle Tumor
Blood
Lymph node
Kidney
 
Figure 7.6 Fluorescence imaging of a KS SLK xenograft tumor bearing mouse and the 
excised organs using (i) 785 nm excitation illumination and 830 nm collection optics for 
IRDye800 and (ii) 660 nm excitation and 710 nm collection optics for Cy5.5.  The arrow 
indicates popliteal node in the tumor region. 
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 Figure 7.6 shows white light images, single wavelength fluorescence images for 
NIR and red light, and overlayed images of both NIR and red light images for the whole 
mouse and the excised organs.  High background signal from excitation at 660 nm and 
emission at 710 nm limited the detection sensitivity.  Overlaying single wavelength 
fluorescence images from the excised organs shows that 111In-DTPA-K(IRDye800)-
c(KRGDf), which targets αvβ3, and Cy5.5, which nonspecifically marked the lymph 
nodes, both accumulated within the tumor region. 
 
7.4 Discussion 
 In the past, angiogenesis has provided a hallmark for characterizing cancers as 
well as several other diseases. As discussed in Section 2, αvβ3 integrins play an 
important role in tumor angiogenesis [18].  Recently, the role of lymphangiogenesis has 
also been implicated in cancer progression [143].  Lymph vessels control fluid 
homeostasis, immunity and possibly metastasis. Although extensive research on 
lymphatics has been performed, our understanding of the fine structure and function of 
the lymphatic system has progressed slowly [143]. 
 Currently, there are few methods capable of in vivo imaging of the lymph system 
in a small animal.  Since lymphatic vessels are relatively small and difficult to locate, 
there is a need for new delivery devices and imaging modalities with high sensitivity 
which could be developed into a real-time dynamic imaging system for the lymph system.  
In this Section, we demonstrated preliminary real-time fluorescence imaging of 
lymphatics associated with human Kaposi’s sarcoma (KS SLK).  The 26-, 31-, and 34-
 
 
 
114
gauge needles delivered agents into the dermal space for uptake into the lymphatic 
system in the mouse.  Lymph nodes were detectable ~ 5 min after injection of fluorescent 
contrast agents.  Additionally, as shown in Figure 7.2, secondary lymph node was 
detected 20 min after the injection.  Fluorescence image-guided lymphadenectomy was 
successfully performed as shown in Figure 7.2 and 7.6.  As an intraoperative imaging 
system described by Kim et al. [144], dynamic fluorescence imaging using an appropriate 
imaging system may be able to track lymph flow in real time and to guide resection of 
lymph nodes in cancer patients.   
 As previously discussed in Section 6, NIR excitable dyes, such as IRDye800 and 
Cardiogreen which were used in this study, resulted in reduced background signal and 
enhanced the detection ability, especially when compared with Cy5.5 imaging in the 
mouse abdomen.  Fluorescence images in mice injected with Cy5.5 showed high 
autofluorescence near G.I. tract resulting from mouse diet, resulting in the limited 
detection of secondary lymph nodes as shown in Figure 7.6 and 7.7.   
 The popliteal nodes were detected in human Kaposi’s sarcoma xenograft bearing 
mice following i.d. delivery of Cy5.5 to the rear left limb.  In addition, in the posterior 
view of the mouse, the lymphatics were fluorescent up to 2 hrs after injection of Cy5.5 as 
shown in Figure 7.5 possibly due to lymphangiogenesis.  Only lymph nodes but no 
lymphatic vessels were detected in a non-tumor bearing mouse during fluorescence 
imaging.  Overlaid fluorescence images from excised organs showed that cold 111-In-
DTPA-K(IRDye800)-c(KRGDf) and Cy5.5 were colocalized into tumors.   
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 Although the imaging in Figure 7.6 required changing out the appropriate filter 
sets for fluorescence imaging with each specific wavelength, our results showed that 
dynamic multi-wavelength fluorescence imaging is promising and thus is explored 
further in the following section as a method for near simultaneous imaging of different 
agents targeting different markers in the xenografts. 
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8. DYNAMIC MULTI-WAVELENGTH WHOLE-BODY FLUORESCENCE 
IMAGING WITH LIQUID CRYSTAL TUNABLE FILTER 
 In Section 5, we demonstrated dynamic real-time fluorescence imaging, which 
enabled the tracking of NIR contrast agents through the whole body of mouse as well as 
the delineation of normal and diseased tissues.  Additionally, in Section 7, we showed 
multi-wavelength fluorescence imaging of tumor and intact lymph nodes.  The 
experimental studies described in this section describe developments for dynamic multi-
wavelength fluorescence imaging after simultaneous injection of multiple contrast agents.  
Most importantly, the developments represent a step towards using our technology for 
image-guided surgery.  The synthesis of contrast agents described in this section was 
performed by Dr. Wei Wang.  Therefore, the experimental aspects related to contrast 
agents are discussed briefly for completeness. 
 
8.1 Introduction 
 Multi-spectral fluorescence imaging techniques can improve diagnoses due to 
fluorescence spectra and emission intensity of the different chromophores [145-147].  A 
liquid crystal tunable filter (LCTF) has been used for acquiring spectral imaging, by 
allowing only light in a narrow wavelength range to reach the camera.  In addition, the 
LCTF can allow rapidly switching of the peak position of the bandpass within 
milliseconds with about 1-nm precision [148, 149].  A series of fluorescence images can 
thus be rapidly acquired at different wavelengths to create spectral or dynamic multi-
wavelength imaging data.  Spectral imaging data can be further used to identify, separate 
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and remove the contribution of autofluorescence in analyzed images [150].  Multi-
wavelength fluorescence imaging may also have the potential to (i) image and colocalize 
multiple targets, (ii) assess differential expression levels of multiple targets, and (iii) 
image response to targeted therapies. 
Although near infrared (NIR) fluorescence imaging technology has gained a 
considerable amount of interest for possible applications in medicine due to low tissue 
absorption in NIR range, NIR fluorescence continuous-wave (CW) imaging is conducted 
in a dark room to maximize its sensitivity.  To use NIR fluorescence optical imaging 
systems during human surgery, “white light” or visible light should be provided 
simultaneously with NIR light or “invisible” light so that the surgeon can identify tissues 
within the surgical field.  Recently, Grand et al. [151] reported intraoperative NIR 
fluorescence imaging system.  They used two laser sources, one providing NIR excitation 
light and the other “white” light via appropriate filters.  In addition, a separate camera 
system was used to detect each light.  Two lights, visible light and fluorescence light, 
were optically separated by a dichroic mirror and barrier filters, and detected by each 
camera.  They successfully demonstrated their imaging system in large animal surgery.  
However, their intraoperative imaging was not dynamic and was limited to one specific 
fluorescence wavelength.  For each additional wavelength to be imaged another light 
laser source and camera with the appropriate filter set must be added.   
 Herein, we demonstrate dynamic real-time whole-body multi-wavelength imaging 
using a liquid crystal tunable filter (LCTF).  Since several different emission wavelengths 
can be selected after tuning LCTF, we showed dynamic fluorescence imaging in two 
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wavelengths in mice bearing M21 and M21L xenografts after injection of mixture of 
111In-DTPA-K(IRDye800)-c(KRGDf), targeting αvβ3, and non-specific agents, Cy5.5.  
In addition, since excitation light reflection can be used for “white” light images when 
LCTF transmits shorter wavelengths than the peak in the excitation light spectrum, 
fluorescence images and white light images can be dynamically acquired, enabling 
image-guided surgery.  Finally, we compared the LCTF performance with a set of a 
holographic notch-plus band rejection filter with a narrow-band interference filter in 
order to assess excitation light leakage, which limits sensitivity in fluorescence imaging. 
 
8.2 Materials and Methods 
8.2.1 Fluorescence Imaging System 
 For fluorescence-enhanced imaging, appropriate wavelengths were selected to 
elicit fluorescence from embedded fluorophores.  In these studies, the excitation light was 
provided by laser diodes (785-nm, 85-mW for IRDye800; 660-nm, 35-mW for Cy5.5, 
Thorlabs, Inc, NJ) at the selected wavelengths.  The excitation light uniformly 
illuminated the whole surface area (10 X 10 cm) through convex lenses and diffusers.  
Each laser has a diode driver and temperature controller (ThorLabs, Inc., models 
LDC500 and TEC2000, respectively, Newton, NJ) to maintain a constant wavelength.   
For multi-spectral and multi-wavelength imaging, a LCTF (Model: SNIR, 
VariSpec, CRI Inc, Woburn, MA) was used.  The LCTF was placed in front of a 28 mm 
lens with a camera adapter thread ring.  Placing the LCTF in front of the lens provides the 
accurate focus adjustment for calibration of the lens as shown in Figure 8.1.  The imaging 
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system was designed so that the field of view could be varied from 5 X 5 cm to over 10 X 
10 cm by varying the focal length of the 28-mm lens used to focus the image onto the 
EMCCD camera.  Figure 8.1 shows a schematic of a multi-wavelength and multi-
fluorescence imaging system.  All serial commands sent through the USB interface to 
control the LCTF were ASCII text, which were scripted in V++ image acquisition 
software.  Therefore, the LCTF was controlled using the image acquisition software, 
programmed with scripts to synchronize the frame transfer from the EMCCD camera, 
resulting in dynamic multi-wavelength imaging due to rapid tuning of wavelengths with 
the LCTF. 
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Figure 8.1 Schematic of multi-wavelength whole-body fluorescence imaging system with 
the LCTF. 
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For transmission of fluorescent light, LCTF was tuned for the specific emission 
wavelengths, i.e. 830-nm for IRDy800 and 710-nm for Cy5.5.  For white light images, a 
shorter wavelength in the excitation light spectrum of Cy5.5, i.e. 650-nm was transmitted.  
For comparison of filter performance, the set of the holographic notch-plus band 
rejection filter (660-nm center wavelength for Cy5.5, OD at λx reported to be >6, 785-
nm center wavelength for IRDye800; Kaiser Optical Systems, OD at λx reported to be 
>6, Inc., Ann Arbor, MI) and narrow-band interference filter (830-nm center wavelength 
for IRDy800, OD at λx reported to be 4, 710-nm center wavelength for Cy5.5 OD at λx 
reported to be >3; CVI Laser Corporation, Albuquerque, NM) were fitted with a 28 mm 
lens to reject back-scattered and reflected excitation light while collecting fluorescence 
emission light.  Fluorescence emission light was detected by electron multiplication 
charge-coupled device (EMCCD) camera.  All fluorescence images acquired in this study 
were taken at 800 msec of EMCCD integration time. 
 
8.2.2 In vitro Experiments 
 For multi-spectral and multi-wavelength imaging, 1 nmol of IRDye800 in 0.2 ml 
of saline, 1nmol of Cy5.5 in 0.2 ml of saline, and 0.2 ml of saline were imaged with the 
LCTF.  At first, wavelength-resolved spectral imaging with LCTF and LCTF with 
holographic notch filters of Cy5.5 and IRDye800 were carried out with both lasers turned 
on.  The tunable filter was stepped from 650 to 1000 nm in 10 nm increments.  Multi-
wavelength fluorescence imaging was dynamically performed for 40 min after setting 
wavelengths at 650 nm for “white” light imaging, and 710 and 830 nm for fluorescence 
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imaging of Cy5.5 and IRDye800, respectively. The mean of the fluorescence intensities 
for each dye in each fluorescence image using the different filters was then calculated. 
 For an analysis of background rejection by each filter, fluorescence imaging was 
performed after filters were coupled by the following combinations: (1) LCTF; (2) LCTF 
with the holographic notch filter; (3) a single bandpass filter; and (4) a bandpass filter 
with the holographic notch filter.  LCTF was set at 710 nm for Cy5.5 and 830 nm for 
IRDye800.  CW measurements were taken with the different optical filters with and 
without IRDye800 and Cy5.5 added at 25 μM of IRDye800 and Cy5.5 in a 2 % liposyn 
suspension.  The images of the uniform media in the presence and absence of each 
fluorophore provide a method to assess excitation leakage.  The transmission ratio for 
each collection optic is defined as: 
                                                 R  ( )
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λ λ= −                                                 (6.1) 
where S(λx) is the mean fluorescence intensity values associated with the measurements 
taken in the absence of IRDye800 and Cy5.5 in the solution and S(λm) is averaged from 
the pixel intensity values associated with the measurements taken in the presence of 
IRDye800 or Cy5.5 in the solution.  The S(λx) signal represents “out of band” 
transmission signal, whereas the difference, S(λm) - S(λx), when taken at the same 
experimental condition, represents the “in-band” transmission signal. 
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8.2.3 In vivo Experiments 
 For in vivo imaging studies, six to eight week-old female SCID mice (18-22g) 
were purchased from Charles River, Inc, Wilmington, MA.  Animals were housed in a 
pathogen-free mouse colony in the Frensley Center for Imaging Research (Baylor 
College of Medicine). The animal protocol was approved by the American Association 
for Laboratory Animal Care and all experiments were conducted in accordance with 
guidelines of the Institutional Animal Care and Use Committee.   
 Human melanoma M21 (integrin αvβ3 positive) and M21L (integrin αvβ3 
negative) cells (2-3 × 106 / animal) were implanted subcutaneously into the left thigh 
region of mice.  Tumors were allowed to grow approximately ~ 6 mm in size.  Before 
administration of imaging agent, animals were placed on a temperature-controlled 
heating pad (Spin System, Australia) at 37 C under isofluorane anesthesia (VetEquip, 
Pleasanton, CA and IsoSol Isofluorane USP, VEDCO Inc., St. Joseph, MO).  A tail vein 
catheter was inserted into each animal.  Dual-labeled RGD peptides for optical and 
nuclear imaging, 111In-DTPA-K(IRDye800)-c(KRGDf) [55, 152] (5 nmol in 200 µl of 
saline) [55] and Cy5.5 (5 nmol in 200 µl of saline) were injected into the tail vein of an 
anesthetized mouse with a constant injection rate (30 ml/min) controlled by a syringe 
pump (Model: PHD 2000, Harvard Apparatus in Holliston, MA).  Multi-wavelength 
dynamic fluorescence images with the LCTF were obtained immediately following the 
injection of the imaging agents for approximately 40 min and at 24 and 48 hrs following 
injection of contrast agents.  Fluorescence images from Cy5.5 and IRDye800 were also 
acquired with a bandpass filter and a holographic notch filter described previously at 24 
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and 48 hrs after the injection of the two contrast agents.  In addition, scintigrams were 
acquired.  Tumor and normal regions of interest (ROIs) were defined from “white” light 
images after collecting 650 nm reflected light.  The mean of the fluorescence intensity 
within each ROI for each fluorescence image was then calculated.  TBR was calculated 
by dividing the mean intensity in the tumor ROI by that in the contralateral normal ROI.   
 
8.2.4 Software and Data Analysis 
 All images were acquired by a personal computer using V++ imaging software 
(Digital Optics, Auckland, New Zealand).  The LCTF offers USB interface, which 
provides complete control of LCTF using a series of ASCII commands.  V++ can control 
LCTF with ASCII commands, resulting in synchronization with the EMCCD camera.  
For tuning wavelengths with the LCTF, a 150 ms transition time at room temperature was 
added to the image acquisition program.  Data analysis was accomplished with Matlab 
software (The MathWorks, Inc., Natick, MA), SigmaPlot software package (SPSS Inc., 
Chicago, IL), and ImageJ (National Institutes of Health, Washington, DC) after 
completion of the image acquisition.  The transmission ratios were compared with the 
student t-test SPSS 12.0.1 statistical program (SPSS, Inc., Chicago, Illinois).  If p < 0.05, 
the results are considered statistically significant. 
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8.3 Results 
8.3.1 Multi-wavelength and Spectral Imaging 
 Dynamic dual fluorescence imaging of vials filled with IRDye800, Cy5.5, and 
normal saline as a control was conducted for 40 min to test the stability and 
synchronization of the LCTF and the camera during dynamic imaging.  Figure 8.2 shows 
the normalized fluorescence intensity vs. time profiles within each ROI.  Dynamic 
fluorescence intensities from IRDye800 and Cy5.5 were constant during dynamic 
imaging with three different wavelengths in sequence, one “white” light and two 
fluorescence images as shown in Figure 8.3.   
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Figure 8.2 Fluorescence intensity vs. time profiles from ROIs in vials filled with 
IRDye800 and Cy5.5 for 40 min. 
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 Figure 8.3 shows a “white” light image and fluorescence images of Cy5.5 and 
IRDye800, all of which were acquired with the LCTF at the respective emission 
wavelengths.  Figure 8.4 shows fluorescence intensity vs. wavelength profiles for the 
spectral imaging.  When the LCTF was used, two peaks were detected from the two 
excitation lights, 660 nm for Cy5.5 and 785 nm for IRDye800.  In addition, two emission 
peaks were detected at 700 nm for Cy5.5 and 800 nm for IRDye800.  When both 
holographic notch filters for Cy5.5 and IRDye800 were coupled with the LCTF, the two 
excitation light peaks were removed, and the emission peak of IRDye800 was shifted to 
810 nm.  Fluorescence emission intensities from Cy5.5 were reduced by 23 % at 700 nm, 
while signals from IRDye800 were reduced by 87 % at 800 nm and 34 % at 810 nm. 
 
(a) (b) (c)
 
 
 
Figure 8.3 Images collected from the LCTF.  “White” light image after transmitting the 
wavelength at 650 nm (a) and fluorescence images from vials filled with IRDye800 (b) 
and Cy5.5 (c) after transmitting wavelengths at 710 nm and 830 nm, respectively. 
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Figure 8.4 Fluorescence intensities from spectral imaging of 1 nmol of IRDye800 and 
Cy5.5 in 200 µl of saline and 200 µl of saline with (a) LCTF, and (b) LCTF with a 
holographic filter. 
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8.3.2 Background Rejection 
 As shown in Figure 8.4 (a), the emission peaks from IRDye800 and Cy5.5 are 800 
nm and 700 nm, respectively.  For comparison of filter performance for background 
rejection, however, LCTF transmitted fluorescence at 710 nm for Cy5.5 and at 830 nm 
for IRDye800.  Table 8.1 shows, in-band, out-of-band, and transmission ratios acquired 
in the absence and presence of IRDye800 or Cy5.5 with optical filter combinations of (1) 
bandpass; (2) bandpass and holographic filters; (3) LCTF; and (4) LCTF and holographic 
filter.  The transmission ratios with a single bandpass filter were the highest in 25 μM 
IRDye800 (p<0.05) and 25 μM Cy5.5 liposyn suspension (p<0.05) as expected.  The 
transmission ratios with a bandpass filter and a holographic filter, LCTF, and LCTF with 
a holographic filter were similar.  However, in-band transmission with a bandpass filter 
and a holographic filter, which are currently used in small animal imaging in our lab, was 
reduced by more than two orders of magnitude over the LCTF and the LCTF with a 
holographic filter (Table 8.1).   
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Table 8.1 Average intensity (in-band and out-of-band) and corresponding transmission 
ratios from 25 μM of IRDye800 and 25 μM of Cy5.5 in a 2 % liposyn suspension. Errors 
are represented as standard deviation values. 
 
 Cy5.5 
 In-band Off-band 
Transmission 
ratio 
A bandpass filter 38130 ± 47 7641 ± 27 0.20 ± 0.001 
A bandpass filter with a 
holographic filter 
35132 ± 72 6162 ± 10 0.17 ± 0.0003 
LCTF 16533 ± 51 2869 ± 39 0.17 ± 0.002 
LCTF with holographic 
filter 
14421 ± 14 2290 ± 5 0.15 ± 0.0003 
    
 IRDye800 
 In-band Off-band 
Transmission 
ratio 
A bandpass filter 44935 ± 48 16201 ± 40 0.36 ± 0.001 
A bandpass filter with a 
holographic filter 
49498 ± 11 6624 ± 2 0.13 ± 0 
LCTF 19058 ± 17 2256 ± 7 0.11 ± 0.0003 
LCTF with holographic 
filter 
14575 ± 43 1812 ± 2 0.12 ± 0.0002 
 
8.3.3 In vivo Imaging 
 Figure 8.5 shows the normalized fluorescence intensity vs. time profiles in the 
tumor and contralateral normal tissue ROIs in mice bearing M21 (a) and M21L (b) 
immediately following the injection of 111In-DTPA-K(IRDye800)-c(KRGDf) and Cy5.5.   
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Figure 8.5 Normalized fluorescence intensity vs. time profiles from xenografts of M21 
(a) and M21L (b) that received an injection of the IRDye800 conjugated RGD and Cy5.5 
at each 5 nmol in 200 µl of normal saline, acquired from the tumor (red) and normal 
tissue (blue) ROIs.  Emission wavelengths for Cy5.5 and IRDye800 were set as 710 nm 
and 830 nm, respectively. 
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Figure 8.5 continued 
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 Emission wavelengths for Cy5.5 and IRDye800 were set at 710 nm and 830 nm, 
respectively.  Fluorescence intensities were acquired during dynamic multi-wavelength 
imaging, which took a series of fluorescence images of red light excitable and NIR 
fluorescent dyes.  Fluorescence intensities in tumor ROIs showed higher accumulation 
than those in normal ROIs in M21 xenografts after injection of integrin αvβ3 targeting 
IRDye800 conjugated RGD (Figure 8.5).  The amount of targeted agent in the tumor 
ROIs for the M21 xenografts increased over time.  Non-specific, Cy5.5 showed similar 
accumulation in both normal and tumor ROIs.  Fluorescence intensities in the tumor 
ROIs of M21L xenografts rapidly increased, then slowly decreased over 40 min 
following the injection of IRDye800 conjugated RGD, while intensities in normal ROIs 
in the M21L model were similar to those in the M21 model.  In addition, fluorescence 
intensities in the normal ROIs in M21L xenograft bearing mice injected with Cy5.5 were 
higher or similar to those in the tumor ROIs.    
 Figures 8.6 and 8.7 show normalized fluorescence images using the bandpass and 
holographic filter sets, and LCTF in mice bearing a subcutaneous M21 (Figure 8.6) and 
M21L (Figure 8.7) human melanoma tumor on the left posterior limb 24 hours after the 
injection of 5 nmol of free Cy5.5 in 200 µl of saline and 5 nmol of 111In-DTPA-
K(IRDye800)-c(KRGDf) in 200 µl of saline.  The M21 tumors were clearly detected in 
both normalized NIR fluorescence images with the bandpass and holographic filter set 
and LCTF.  In addition, M21 tumors were shown in SPECT/CT images (Figure 8.6 (e)).   
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Figure 8.6 Normalized fluorescence images ((a), (b), (c), and (d)) and SPECT/CT image 
(e).  Fluorescence images were acquired with a bandpass and holographic filter set ((a) 
and (b), and LCTF ((c) and (d)) in mice bearing M21 24 hr after injection of 111In-DTPA-
K(IRDye800)-c(KRGDf) ((a) and (c)) and Cy5.5 ((b) and (d)). The arrow indicates the 
tumor location. 
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Figure 8.7 Normalized fluorescence images from a bandpass filter and holographic filter 
set ((a) and (b), and LCTF ((c) and (d)) in mice bearing M21L 24 hr after injection of 
111In-DTPA-K(IRDye800)-c(KRGDf) ((a) and (c)) and Cy5.5 ((b) and (d)). The arrow 
indicates the tumor location. 
 
 Fluorescence images with Cy5.5 show no tumor detection, greater excitation light 
leakage, and higher autofluorescence compared to those with IRDye800 as discussed in 
Section 5.  The M21L tumor was not delineated in NIR or red light excitable fluorescence 
images, because it has no αvβ3 integrin.  Autofluorescence and as excitation light leakage 
were detected in the red light excitable fluorescence images. 
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LCTFWhite light image Bandpass filter with  holographic filter
(a) (b) (c)
 
Figure 8.8 “White” light (a), NIR using the LCTF (b) and NIR using the bandpass filter 
and holographic filters (c) in mice of M21 24 hr after injection of 111In-DTPA-
K(IRDye800)-c(KRGDf). The arrow indicates the tumor location. 
 
Figure 8.8 shows the “white” light image from the LCTF and NIR fluorescence 
images from the LCTF, and a bandpass filter and holographic filter set in M21 xenografts 
24 hr after the injection of 111In-DTPA-K(IRDye800)-c(KRGDf).  As shown in Table 6.1, 
fluorescence intensities in tumor ROIs were more than two times lower with LCTF than 
those with a bandpass filter and holographic filter.  Figure 8.9 shows TBR values in M21 
xenografts 24 hr after injection of 111In-DTPA-K(IRDye800)-c(KRGDf) and Cy5.5.  
TBRs from NIR fluorescence images with a bandpass and holographic filter were not 
statistically different from those with LCTF.  TBRs from red light excitable fluorescence 
images were also similar in each filter configuration. 
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Figure 8.9 Tumor to background ratio (TBR). The black and gray columns denote the 
mean value of each test group 24 hour after the injection of the IRDye800 conjugated 
RGD and Cy5.5 with LCTF and a bandpass filter and holographic filter, respectively, and 
the error bars represent the standard deviation.  
 
 
8.4 Discussion 
In this section, we demonstrated dynamic multi-wavelength whole-body 
fluorescence imaging using the LCTF.  As shown Figure 8.1, the LCTF was mounted to 
the front of a lens attached directly to a camera.  In this configuration, the lens can be 
focused normally.  A filter with a 10 mm aperture was used and successfully prevented 
vignetting of the fluorescence images.  A compact electronics controller box is connected 
to the filter’s optics housing, to accept serial commands from the host computer.  
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Therefore, a simple program can be used to control the LCTF for synchronization with a 
camera though an available USB port on a PC-compatible computer.  Since (i) the LCTF 
can be set to allow the light from a narrow set of wavelengths to reach the camera and (ii) 
the peak position of this bandpass can be rapidly switched to any other position within 
150 milliseconds, a series of dynamic multi-wavelength images could be rapidly acquired 
at different wavelengths.  Additionally, since no filter wheel is needed, images are 
registered perfectly.  During dynamic multi-wavelength fluorescence imaging for 40 min, 
tuning wavelengths with the LCTF was synchronized with the camera (Figure 8.2). 
Dynamic multi-wavelength imaging can be used to correct for blood perfusion 
when the accumulation of targeting agent in different xenograft tumor models is 
compared as shown previously in dual energy window in SPECT [96] which was 
discussed in Section 2.  Furthermore, it can be used to image several different locations 
with different targeted fluorescence conjugates, such as the tumor neovasculature or the 
tumor cells themselves or the tumor lymphatics.  In addition to multi-wavelength 
fluorescence imaging, when shorter wavelengths than that excitation peak are transmitted 
by the LCTF it is possible to collect visible light images.  The sensitivity to wavelengths 
between 400 and 700 nm is more than two logs lower than that of those above 700 nm 
[151], allowing for the capture of visible light which can be used for “white” light images 
to guide a surgeon within the surgical area during fluorescence imaging.  Figures 8.3 and 
8.8 show “white” light images collected by transmitting 650 nm light, and fluorescence 
images, IRDye800 collected by transmitting 830 nm light and Cy5.5 with 710 nm light.  
Both multi-wavelength imaging and spectral imaging have been also used in medicine.  
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In a melanoma tumor, for example, spectral imaging can overcome the problem of 
pigment interference in the human melanocytic progression pathway [146].   
 However, the nonuniformity of the excitation light may cause the nonuniform 
fluorescence generation seen from area illumination in the phantom and from the small-
animal studies as shown in Cy5.5 fluorescence images (Figures 8.6 and 8.7).  Houston et 
al. [45] showed that the different filter combinations alter (i) the transmission of 
specularly reflected and diffusely propagated excitation light, (ii) the transmission of 
generated emission light, and (iii) the spatial distribution of intensities.  Since the LCTF 
uses polarization in the spectral selection process, transmission efficiencies are typically 
in the 30%-range while traditional interference filters transmit approximately 90% of the 
incoming light.  As shown in Table 6.1, fluorescence signals from LCTF are reduced by 
59% for Cy5.5 and 70% by IRDye800 as compared to each set of a bandpass and 
holographic filter set.  Therefore, the contribution of excitation light leakage to lower 
transmission efficiencies should be studied.  Since the expanded laser beam intensity was 
nonuniform and covered an area smaller than that of the imaged surface, a region of 
uniform excitation light delivery in the center of the images was selected, covering an 
area ~5 cm-diameter.  The image of the surface of the tissue phantom in the presence and 
absence of IRDye800 and Cy5.5 was used to assess excitation light leakage.  Table 6.1 
shows that transmission ratios from a bandpass filter with a holographic filter were 
similar to those from LCTF and LCTF with a holographic filter, indicating similar 
capacity to reject excitation light leakage.  Lower transmission efficiencies can be 
improved by increasing camera gain, integration time, and laser power.  Nonetheless, 
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NIR fluorescence images after using LCTF in mice bearing M21 tumors showed clear 
visualization of the tumors.  In addition, TBR from a bandpass filter with a holographic 
filter was not significantly different from that with the LCTF (p>0.05).  Therefore, the 
benefit of spectral information as well as dynamic multi-wavelength may outweigh the 
impact of the lower transmission efficiencies, and could enable in vivo small animal 
imaging and ultimately clinical imaging. 
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9. SUMMARY AND CONCLUSIONS 
 
 A novel fluorescence imaging modality has been developed for non-invasive 
dynamic small animal imaging, and ultimately for human clinical trials.  Fluorescence 
imaging was conducted with contrast agents specifically targeted to disease markers, 
enabling the detection of cancerous regions and measurement of therapeutic efficacies.  
The continuous wave (CW) fluorescence imaging modality consists of an intensified 
charge-coupled device (ICCD) or an electron-multiplying CCD (EMCCD) camera, both 
capable of detecting low fluorescence emission signals.  In addition to high sensitivity, 
the fluorescence imaging modality allows for sub-second camera integration time even 
for small amounts of contrast agent.  Therefore, dynamic fluorescence imaging should be 
able to track biodistribution and differentiate between tumor and normal tissue regions.  
The work presented in this thesis was conducted to (i) assess dose-dependent uptake 
using dynamic fluorescence imaging with pharmacokinetic (PK) models, (ii) evaluate 
disease target availability in potentially different tissue compartments in two different 
xenograft tumor models, (iii) compare the impact of autofluorescence in fluorescence 
imaging with NIR vs. red light excitable fluorescent contrast agents, (iv) examine 
fluorescence image-guided surgery and dual-wavelength fluorescence imaging of 
different tissues or targets, and (v) develop dynamic multi-wavelength whole-body 
fluorescence imaging with more than two different fluorescent contrast agents.  The 
following conclusions were reached in the studies discussed above. 
1. Dynamic fluorescence images were obtained from subcutaneous human 
Kaposi’s sarcoma (KS1767) xenografts immediately following the i.v 
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injection of integrin targeting Cy5.5-c(KRGDf) at doses from 0.75 to 6 
nmol/mouse.  The fluorescence images were acquired using an intensified 
charge-coupled device (ICCD) system and were analyzed with a three-
compartment pharmacokinetic (PK) model to determine uptake parameters in 
the tumor and normal tissue regions of interest as a function of administered 
dose.  PK analysis showed that the uptake of Cy5.5-(KRGDf) in tumor 
regions were; (i) significantly greater than the contralateral normal tissue 
regions; (ii) linearly increased with dose of Cy5.5-c(KRGDf) up to 1.5 
nmol/mouse; and (iii) were blocked by pre-injection of c(KRGDf).  Above 
doses of 1.5 nmol/mouse, the uptake no longer increased with dose, 
suggesting integrin receptor saturation.  In normal tissues, the PK uptake 
parameters were not influenced by Cy5.5-c(KRGDf) dose or 
preadministration of c(KRGDf). 
2. Dynamic in vivo fluorescence optical imaging can enable assessment of early 
αvβ3 receptor availability in potentially different compartments: (i) on the 
proliferating endothelium within the vascular space, and/or (ii) on the surface 
of cancer cells in the extravascular space.  In this study, xenografts bearing  
human Kaposi’s sarcoma (KS1767) and human melanoma tumor (M21) were 
imaged following i.v. injection of αvβ3 targeting fluorescent contrast agent, 
Cy5.5-c(KRGDf).  The tumor and contralateral normal tissue regions were 
evaluated using pharmacokinetic (PK) models and target to background ratios 
(TBRs).  TBR and PK analysis showed that KS1767 exhibited early and rapid 
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uptake of Cy5.5-c(KRGDf) which was blocked by the prior administration of 
c(KRGDf) as a competitive binder to αvβ3.  The results indicate that vascular 
αvβ3 receptors are readily available for Cy5.5-c(KRGDf) targeting as well as 
for competitive ligand with c(KRGDf).  M21 tumors showed different 
characteristics from KS1767, with non-significant differences of TBR and 
early uptake rates between M21 and contralateral normal tissue regions.  
These results are consistent with the extravascular location of αvβ3 receptors 
on M21 cancer cells.  Dynamic fluorescence imaging may provide insights 
into the different tissue compartments and mechanisms of therapeutic action 
of anti-angiogenic and cytotoxic agents. 
3. Dynamic real-time fluorescence imaging was used to evaluate the impact of 
endogenous fluorescence with near infrared (NIR) and red light excitable 
fluorescent conjugates, IRDye800-EGF (780/830 nm Ex/Em) and Cy5.5-EGF 
(660/710 nm Ex/Em), respectively in mice bearing epidermal growth factor 
receptor (EGFR) positive xenografts.  Fluorescence images were taken every 
1.1 sec for a period of approximately 8 seconds immediately following i.v. 
injection of 1 nmol of IRDye800-EGF or Cy5.5-EGF each fluorescent 
contrast agent.  Imaging showed fast distribution of fluorescent contrast agent 
through the chest, kidney, and head regions of interest (ROIs) in animals 
injected with IRDye800-EGF with excitation at 780 nm.  The tumor was 
detected 4.4 sec after injection of IRDye800-EGF due to high permeability.  
However, internal organs were not seen upon injection of Cy5.5-EGF due to 
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high background autofluorescence from 660 nm excitation. When the TBR vs. 
time profiles were plotted for the chest, kidneys, and head as target ROIs 
using the stomach as the background ROI, the results showed that the TBR 
was significantly higher in mice injected with IRDye800-EGF than with 
Cy5.5-EGF.  The low background at 830 nm autofluorescence measured 
through bandpass filter with 780 nm excitation made it possible not only 
image deep tissues, but also to evaluate near real-time biodistribution at early 
injection time points using dynamic fluorescence imaging. 
4. NIR fluorescence images showed the uptake of fluorescent contrast agents in 
human Kaposi’s sarcoma (KS SLK) tumor models.  After NIR imaging, 24 
hrs following injection of fluorescent conjugates, a second red light excitable 
fluorescent dye was injected and after 5 min, the lymphatics were imaged in 
the tumor region.  The lymph nodes were then successfully dissected, as 
guided by fluorescence imaging.  Dual-wavelength fluorescence imaging can 
be applied to characterize tumors by targeting different tissues, such as blood 
vessels, lymphatics, or tumors.  Therefore, the ability to image both 
angiogenic and lymph vasculatures and follow the response to treatment will 
improve understanding of disease progression which should translate into 
more effective clinical therapeutics. 
5. Whole-body dynamic multi-wavelength fluorescence imaging was 
accomplished using a liquid crystal tunable filter (LCTF).  Since several 
different emission wavelengths can be selected by tuning the LCTF, two 
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wavelength dynamic fluorescence imaging was conducted in mice bearing 
M21 and M21L after injection of mixture of NIR fluorescent conjugated RGD 
peptide targeting to integrin αvβ3 and non-specific dye, Cy5.5.  Dynamic 
multi-wavelength imaging with LCTF can differentiate the uptake of different 
fluorescent contrast agents between tumor and normal tissue ROIs in M21 and 
M21L xenograft models.  Although fluorescence signals through the LCTF 
were two times lower than those from the holographic and bandpass filter set 
used previously, the results showed similar background rejection for both 
filter setups.  In addition, LCTF can transmit shorter wavelengths than the 
peak in the excitation light spectrum, allowing excitation light to be used for 
“white” light images.  Therefore, fluorescence images and white light images 
can be dynamically acquired one by one, which should enable image-guided 
surgery. 
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